Tilray Brands (TLRY) 10-Q 9 Apr 24 2023 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Feb. 29, 2024	Apr. 05, 2024
Document Information [Line Items]
Entity Central Index Key	0001731348
Entity Registrant Name	Tilray Brands, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--05-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Feb. 29, 2024
Document Transition Report	false
Entity File Number	001-38594
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-4310622
Entity Address, Address Line One	265 Talbot Street West
Entity Address, City or Town	Leamington
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	N8H 5L4
City Area Code	844
Local Phone Number	845-7291
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	TLRY
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		774,028,558

Consolidated Statements of Fina

Consolidated Statements of Financial Position (Current Period Unaudited) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Current assets
Cash and cash equivalents	$ 146,253	$ 206,632
Marketable securities	79,605	241,897
Accounts receivable, net	89,542	86,227
Inventory	244,139	200,551
Prepaids and other current assets	43,034	37,722
Assets held for sale	28,638	0
Total current assets	631,211	773,029
Capital assets	578,783	429,667
Operating lease, right-of-use assets	17,453	5,941
Intangible assets	930,105	973,785
Goodwill	2,009,632	2,008,843
Interest in equity investees	0	4,576
Long-term investments	8,058	7,795
Convertible notes receivable	32,000	103,401
Other assets	5,614	222
Total assets	4,212,856	4,307,259
Current liabilities
Bank indebtedness	15,029	23,381
Accounts payable and accrued liabilities	209,763	190,682
Contingent consideration	0	16,218
Warrant liability	3,182	1,817
Current portion of lease liabilities	5,424	2,423
Current portion of long-term debt	12,351	24,080
Current portion of convertible debentures payable	83,351	174,378
Total current liabilities	329,100	432,979
Long - term liabilities
Contingent consideration	14,000	10,889
Lease liabilities	73,228	7,936
Long-term debt	165,648	136,889
Convertible debentures payable	126,587	221,044
Deferred tax liabilities, net	161,042	167,364
Other liabilities	210	215
Total liabilities	869,815	977,316
Commitments and contingencies (refer to Note 19)
Stockholders' equity
Common stock ($0.0001 par value; 1,198,000,000 common shares authorized; 774,028,053 and 656,655,455 common shares issued and outstanding, respectively)	77	66
Preferred shares ($0.0001 par value; 10,000,000 preferred shares authorized; nil and nil preferred shares issued and outstanding, respectively)	0	0
Additional paid-in capital	6,030,709	5,777,743
Accumulated other comprehensive loss	(43,187)	(46,610)
Accumulated Deficit	(2,628,741)	(2,415,507)
Total Tilray Brands, Inc. stockholders' equity	3,358,858	3,315,692
Non-controlling interests	(15,817)	14,251
Total stockholders' equity	3,343,041	3,329,943
Total liabilities and stockholders' equity	$ 4,212,856	$ 4,307,259

Consolidated Statements of Fi_2

Consolidated Statements of Financial Position (Current Period Unaudited) (Parentheticals) - $ / shares	Feb. 29, 2024	May 31, 2023
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	1,198,000,000	1,198,000,000
Common stock, shares issued (in shares)	774,028,053	656,655,455
Common stock, shares outstanding (in shares)	774,028,053	656,655,455
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0

Consolidated Statements of Loss

Consolidated Statements of Loss and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Net revenue	$ 188,340	$ 145,589	$ 559,060	$ 442,936
Cost of goods sold	138,944	157,288	418,059	363,139
Gross profit (loss)	49,396	(11,699)	141,001	79,797
Operating expenses:
General and administrative	39,940	38,999	123,769	117,385
Selling	9,995	6,452	24,437	25,792
Amortization	21,558	23,518	65,700	71,872
Marketing and promotion	11,191	7,354	28,934	23,137
Research and development	106	171	241	502
Change in fair value of contingent consideration	(5,983)	352	(16,790)	563
Impairments	0	934,000	0	934,000
Other than temporary change in fair value of convertible notes receivable	42,681	181,376	42,681	181,376
Litigation costs, net of recoveries	3,363	(5,230)	8,439	(1,970)
Restructuring costs	5,178	2,663	8,748	10,727
Transaction costs (income)	3,465	5,382	13,061	(3,882)
Total operating expenses	131,494	1,195,037	299,220	1,359,502
Operating loss	(82,098)	(1,206,736)	(158,219)	(1,279,705)
Interest expense, net	(8,517)	(1,040)	(26,977)	(8,560)
Non-operating income (expense), net	(17,239)	1,213	(20,820)	(50,229)
Loss before income taxes	(107,854)	(1,206,563)	(206,016)	(1,338,494)
Income tax (recovery) expense	(2,871)	(10,811)	1,013	(15,313)
Net loss	(104,983)	(1,195,752)	(207,029)	(1,323,181)
Total net income (loss) attributable to:
Stockholders of Tilray Brands, Inc.	(92,701)	(1,170,998)	(213,234)	(1,313,943)
Non-controlling interests	(12,282)	(24,754)	6,205	(9,238)
Other comprehensive gain (loss), net of tax
Foreign currency translation gain (loss)	(4,696)	6,390	3,716	(78,499)
Unrealized gain (loss) on convertible notes receivable	0	95,345	0	75,177
Total other comprehensive gain (loss), net of tax	(4,696)	101,735	3,716	(3,322)
Comprehensive loss	(109,679)	(1,094,017)	(203,313)	(1,326,503)
Total comprehensive income (loss) attributable to:
Stockholders of Tilray Brands, Inc.	(97,521)	(1,092,491)	(209,811)	(1,336,127)
Non-controlling interests	$ (12,158)	$ (1,526)	$ 6,498	$ 9,624
Weighted average number of common shares - basic (in shares)	754,439,331	615,534,670	725,346,952	597,829,714
Weighted average number of common shares - diluted (in shares)	754,439,331	615,534,670	725,346,952	597,829,714
Net loss per share - basic (in dollars per share)	$ (0.12)	$ (1.9)	$ (0.29)	$ (2.2)
Net loss per share - diluted (in dollars per share)	$ (0.12)	$ (1.9)	$ (0.29)	$ (2.2)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	HT Investments MA LLC Note [Member] Common Stock and Preferred Stock [Member]	HT Investments MA LLC Note [Member] Additional Paid-in Capital [Member]	HT Investments MA LLC Note [Member] AOCI Attributable to Parent [Member]	HT Investments MA LLC Note [Member] Retained Earnings [Member]	HT Investments MA LLC Note [Member] Noncontrolling Interest [Member]	HT Investments MA LLC Note [Member]	TLRY 27 [Member] Common Stock and Preferred Stock [Member]	TLRY 27 [Member] Additional Paid-in Capital [Member]	TLRY 27 [Member] AOCI Attributable to Parent [Member]	TLRY 27 [Member] Retained Earnings [Member]	TLRY 27 [Member] Noncontrolling Interest [Member]	TLRY 27 [Member]	Acquisition of Montauk Brewing Company, Inc. [Member] Common Stock and Preferred Stock [Member]	Acquisition of Montauk Brewing Company, Inc. [Member] Additional Paid-in Capital [Member]	Acquisition of Montauk Brewing Company, Inc. [Member] AOCI Attributable to Parent [Member]	Acquisition of Montauk Brewing Company, Inc. [Member] Retained Earnings [Member]	Acquisition of Montauk Brewing Company, Inc. [Member] Noncontrolling Interest [Member]	Acquisition of Montauk Brewing Company, Inc. [Member]	HEXO Acquisition [Member] Common Stock and Preferred Stock [Member]	HEXO Acquisition [Member] Additional Paid-in Capital [Member]	HEXO Acquisition [Member] AOCI Attributable to Parent [Member]	HEXO Acquisition [Member] Retained Earnings [Member]	HEXO Acquisition [Member] Noncontrolling Interest [Member]	HEXO Acquisition [Member]	Tilray Brands Inc MediPharm / HEXO Litigation Settlement [Member] Common Stock and Preferred Stock [Member]	Tilray Brands Inc MediPharm / HEXO Litigation Settlement [Member] Additional Paid-in Capital [Member]	Tilray Brands Inc MediPharm / HEXO Litigation Settlement [Member] AOCI Attributable to Parent [Member]	Tilray Brands Inc MediPharm / HEXO Litigation Settlement [Member] Retained Earnings [Member]	Tilray Brands Inc MediPharm / HEXO Litigation Settlement [Member] Noncontrolling Interest [Member]	Tilray Brands Inc MediPharm / HEXO Litigation Settlement [Member]	Common Stock and Preferred Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at May. 31, 2022																															532,674,887
Balance at May. 31, 2022																															$ 53	$ 5,382,367	$ (20,764)	$ (962,851)	$ 42,561	$ 4,441,366
Share issuance - equity financing (in shares)																															32,481,149
Share issuance - equity financing																															$ 3	129,590	0	0	0	129,593
Shares issued to purchase HEXO convertible note receivable (in shares)																															33,314,412
Shares issued to purchase HEXO convertible note receivable																															$ 3	107,269	0	0	0	107,272
HTI Convertible Note - conversion feature	$ 0	$ 9,055	$ 0	$ 0	$ 0	$ 9,055
Share issuance - Double Diamond Holdings dividend settlement (in shares)																															1,529,821
Share issuance - Double Diamond Holdings dividend settlement																															$ 1	5,063	0	0	0	5,064
Share issuance - options exercised (in shares)																															3,777
Share issuance - options exercised																															$ 0	0	0	0	0	0
Share issuance - RSUs exercised (in shares)																															950,893
Share issuance - RSUs exercised																															$ 0	0	0	0	0	0
Shares effectively repurchased for employee withholding tax																															0	(1,189)	0	0	0	(1,189)
Stock-based compensation																															0	9,193	0	0	0	9,193
Dividends declared to non-controlling interests																															0	0	0	0	(8,561)	(8,561)
Net comprehensive (loss) income																															$ 0	0	(58,968)	(73,482)	3,839	(128,611)
Share issuance - Settlement of equity component of TLRY 23 convertible note	$ 0	$ (9,055)	$ 0	$ 0	$ 0	$ (9,055)
Balance (in shares) at Aug. 31, 2022																															600,954,939
Balance at Aug. 31, 2022																															$ 60	5,641,348	(79,732)	(1,036,333)	37,839	4,563,182
Balance (in shares) at May. 31, 2022																															532,674,887
Balance at May. 31, 2022																															$ 53	5,382,367	(20,764)	(962,851)	42,561	4,441,366
Net comprehensive (loss) income																																				(1,326,503)
Balance (in shares) at Feb. 28, 2023																															617,977,031
Balance at Feb. 28, 2023																															$ 62	5,723,342	(42,948)	(2,276,794)	3,109	3,406,771
Balance (in shares) at Aug. 31, 2022																															600,954,939
Balance at Aug. 31, 2022																															$ 60	5,641,348	(79,732)	(1,036,333)	37,839	4,563,182
Share issuance - Double Diamond Holdings dividend settlement (in shares)																															10,276,305
Share issuance - Double Diamond Holdings dividend settlement																															$ 1	38,753	0	0	(32,280)	6,474
Share issuance - options exercised (in shares)																															4,183
Share issuance - options exercised																															$ 0	0	0	0	0	0
Share issuance - RSUs exercised (in shares)																															237,611
Share issuance - RSUs exercised																															$ 0	0	0	0	0	0
Stock-based compensation																															0	10,943	0	0	0	10,943
Net comprehensive (loss) income																															$ 0	0	(41,723)	(69,463)	7,311	(103,875)
Shares issuance (in shares)													1,708,521
Shares issuance													$ 0	$ 6,422	$ 0	$ 0	$ 0	$ 6,422
Balance (in shares) at Nov. 30, 2022																															613,181,559
Balance at Nov. 30, 2022																															$ 61	5,697,466	(121,455)	(1,105,796)	12,870	4,483,146
Share issuance - Double Diamond Holdings dividend settlement (in shares)																															4,188,280
Share issuance - Double Diamond Holdings dividend settlement																															$ 1	15,912	0	0	(8,235)	7,678
Share issuance - RSUs exercised (in shares)																															487,192
Share issuance - RSUs exercised																															$ 0	0	0	0	0	0
Stock-based compensation																															0	9,630	0	0	0	9,630
Net comprehensive (loss) income																															$ 0	0	78,507	(1,170,998)	(1,526)	(1,094,017)
Preferred share issuance (in shares)																															120,000
Preferred share issuance																															$ 0	334	0	0	0	334
Balance (in shares) at Feb. 28, 2023																															617,977,031
Balance at Feb. 28, 2023																															$ 62	5,723,342	(42,948)	(2,276,794)	3,109	3,406,771
Balance (in shares) at May. 31, 2023																															656,655,455
Balance at May. 31, 2023																															$ 66	5,777,743	(46,610)	(2,415,507)	14,251	3,329,943
Share issuance - Double Diamond Holdings dividend settlement (in shares)																															5,004,735
Share issuance - Double Diamond Holdings dividend settlement																															$ 0	8,146	0	0	0	8,146
Share issuance - RSUs exercised (in shares)																															3,912,481
Share issuance - RSUs exercised																															$ 0	0	0	0	0	0
Shares effectively repurchased for employee withholding tax																															0	(4,860)	0	0	0	(4,860)
Stock-based compensation																															0	8,257	0	0	0	8,257
Dividends declared to non-controlling interests																															0	0	0	0	(7,891)	(7,891)
Net comprehensive (loss) income																															$ 0	0	3,049	(71,525)	15,822	(52,654)
Shares issuance (in shares)																			39,705,962
Shares issuance																			$ 4	$ 65,158	$ 0	$ 0	$ 0	$ 65,162
Share issuance - acquisition settlement (in shares)																															865,426
Share issuance - acquisition settlement							$ 0	$ 3,953	$ 0	$ 0	$ 0	$ 3,953																			$ 0	1,500	0	0	0	1,500
Share issuance (in shares)																															17,148,541
Share issuance - HTI convertible note																															$ 2	49,998				50,000
Share issuance - HTI convertible note (in shares)																															17,148,541
Balance (in shares) at Aug. 31, 2023																															723,292,600
Balance at Aug. 31, 2023																															$ 72	5,909,895	(43,561)	(2,487,032)	22,182	3,401,556
Balance (in shares) at May. 31, 2023																															656,655,455
Balance at May. 31, 2023																															$ 66	5,777,743	(46,610)	(2,415,507)	14,251	3,329,943
Net comprehensive (loss) income																																				(203,313)
Balance (in shares) at Feb. 29, 2024																															774,028,053
Balance at Feb. 29, 2024																															$ 77	6,030,709	(43,187)	(2,628,741)	(15,817)	3,343,041
Balance (in shares) at Aug. 31, 2023																															723,292,600
Balance at Aug. 31, 2023																															$ 72	5,909,895	(43,561)	(2,487,032)	22,182	3,401,556
HTI Convertible Note - conversion feature																															$ 0	1,672	0	0	0	1,672
Share issuance - RSUs exercised (in shares)																															9,184
Share issuance - RSUs exercised																															$ 0	0	0	0	0	0
Stock-based compensation																															0	8,201	0	0	0	8,201
Net comprehensive (loss) income																															$ 0	0	5,194	(49,008)	2,834	(40,980)
Share issuance (in shares)																															1,032,616
Share issuance - HTI convertible note																															$ 0	2,313	0	0	0	2,313
Share issuance - HTI convertible note (in shares)																															1,032,616
Share issuance - Settlement of litigation claims from MediPharm Labs Inc (in shares)																									1,573,152
Share issuance - Settlement of litigation claims from MediPharm Labs Inc																									$ 0	$ 3,477	$ 0	$ 0	$ 0	$ 3,477
Share issuance - Repurchase of TLRY 23 convertible note (in shares)																															7,000,000
Share issuance - Repurchase of TLRY 23 convertible note																															$ 1	20,457	0	0	0	20,458
Share issuance - Settlement of equity component of TLRY 23 convertible note																															$ 0	(1,672)	0	0	0	(1,672)
Balance (in shares) at Nov. 30, 2023																															732,907,552
Balance at Nov. 30, 2023																															$ 73	5,942,671	(38,367)	(2,536,040)	25,016	3,393,353
Share issuance - Double Diamond Holdings dividend settlement (in shares)																															13,627,391
Share issuance - Double Diamond Holdings dividend settlement																															$ 1	28,599	0	0	(26,217)	2,383
Share issuance - options exercised (in shares)																															4,291
Share issuance - options exercised																															$ 0	0	0	0	0	0
Share issuance - RSUs exercised (in shares)																															260,567
Share issuance - RSUs exercised																															$ 0	0	0	0	0	0
Stock-based compensation																															0	8,059	0	0	0	8,059
Dividends declared to non-controlling interests																															0	0	0	0	(2,458)	(2,458)
Net comprehensive (loss) income																															$ 0	0	(4,820)	(92,701)	(12,158)	(109,679)
Share issuance - HTI convertible note																																				2,313
Share issuance - Repurchase of TLRY 23 convertible note (in shares)																															27,228,252
Share issuance - Repurchase of TLRY 23 convertible note																															$ 3	51,380	0	0	0	51,383
Balance (in shares) at Feb. 29, 2024																															774,028,053
Balance at Feb. 29, 2024																															$ 77	$ 6,030,709	$ (43,187)	$ (2,628,741)	$ (15,817)	$ 3,343,041

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023	May 31, 2023
Cash used in operating activities:
Net loss	$ (104,983)	$ (1,195,752)	$ (207,029)	$ (1,323,181)
Adjustments for:
Deferred income tax recovery			(7,399)	(29,537)
Unrealized foreign exchange (gain) loss			(6,622)	13,711
Amortization			95,183	101,156
Accretion of convertible debt discount			11,463	7,941
Inventory valuation write down			0	55,000
Impairments	0	934,000	0	934,000
Other than temporary change in fair value of convertible notes receivable	42,681	181,376	42,681	181,376
Other non-cash items			13,297	4,990
Stock-based compensation			24,517	29,766
(Gain) loss on long-term investments & equity investments			4,255	2,843
Loss on derivative instruments			13,717	13,534
Change in fair value of contingent consideration	(5,983)	352	(16,790)	563
Change in non-cash working capital:
Accounts receivable			5,578	18,053
Prepaids and other current assets			1,148	(32,680)
Inventory			(4,629)	(11,808)
Accounts payable and accrued liabilities			(30,982)	(1,419)
Net cash used in operating activities			(61,612)	(35,692)
Cash provided by (used in) investing activities:
Investment in capital and intangible assets			(19,539)	(8,394)
Proceeds from disposal of capital and intangible assets			1,166	2,175
Disposal (purchase) of marketable securities, net			162,292	(243,186)
Business acquisitions, net of cash acquired			(60,626)	(28,122)
Net cash provided by (used in) investing activities			83,293	(277,527)
Cash provided by (used in) financing activities:
Share capital issued, net of cash issuance costs			0	129,593
Shares effectively repurchased for employee withholding tax			0	(1,189)
Proceeds from long-term debt			32,621	1,288
Repayment of long-term debt			(17,978)	(64,658)
Proceeds from convertible debt			21,553	0
Repayment of convertible debt			(107,330)	0
Repayment of lease liabilities			(2,771)	(1,114)
Net increase (decrease) in bank indebtedness			(8,352)	2
Net cash provided by (used in) financing activities			(82,257)	63,922
Effect of foreign exchange on cash and cash equivalents			197	(1,615)
Net decrease in cash and cash equivalents			(60,379)	(250,912)
Cash and cash equivalents, beginning of period			206,632	415,909	$ 415,909
Cash and cash equivalents, end of period	$ 146,253	$ 164,997	$ 146,253	$ 164,997	$ 206,632

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	Note 1. The accompanying unaudited condensed interim consolidated financial statements (the “financial statements”) reflect the accounts of the Company for the quarterly period ended February 29, 2024 not 10 May 31, 2023 not These condensed interim consolidated financial statements have been prepared on the going concern basis which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due, under the historical cost convention except for certain financial instruments that are measured at fair value, as detailed in the Company’s accounting policies. All amounts in the unaudited condensed interim consolidated financial statements, notes and tables have been rounded to the nearest thousand, except par values and per share amounts, and unless otherwise indicated. Certain items of the comparative figures have been changed to conform to the presentation adopted in the current period. Basis of consolidation Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of all subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases. All intercompany balances and transactions have been eliminated on consolidation. A complete list of our subsidiaries that existed as of our most recent fiscal year end is included in the Annual Report, except for the entities acquired within Note 7 nine February 29, 2024 Marketable securities We classify term deposits and other investments that have maturities of greater than three one Restricted cash We classify cash that is legally or contractually restricted as to withdrawal or usage as restricted cash. As of February 29, 2024 May 31, 2023, $nil six November 31, 2023, 7 three February 29, 2024, Assets held for sale We classify capital assets that are available for immediate sale in their present condition, which the Company has approved the action or plan to sell, and the sales is probable within one February 29, 2024 3 When there are changes in circumstances that were previously considered unlikely to occur, and it is decided not not Long-term investments Investments in equity securities of entities over which the Company does not Investments in entities over which the Company does not may not 820 Fair Value Measurement Convertible notes receivable Convertible notes receivable includes various investments in which the Company has the right, or potential right to convert the indenture into common stock of the investee and are classified as available-for-sale and are recorded at fair value. Unrealized gains and losses during the year, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders' equity until realized. We use judgement to assess convertible notes receivables for impairment at each measurement date. Convertible notes receivables are impaired when a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the consolidated statements of loss and comprehensive loss and a new cost basis for the investment is established. We also evaluate whether there is a plan to sell the security, or it is more likely than not Revenue Revenue is recognized when the control of the promised goods or services, through performance obligation, is transferred or provided to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for the performance obligations. Excise taxes remitted to tax authorities are government-imposed excise taxes on cannabis and beer. Excise taxes are recorded as a reduction of sales in net revenue in the consolidated statements of loss and comprehensive loss and recognized as a current liability within accounts payable and accrued liabilities on the consolidated balance sheets, with the liability subsequently reduced when the taxes are remitted to the tax authority. In addition, amounts disclosed as net revenue are net of excise taxes, sales tax, duty tax, allowances, discounts and rebates. In determining the transaction price for the sale of goods or services, the Company considers the effects of variable consideration and the existence of significant financing components, if any. We may may may On July 12, 2022, 26 June 22, 2023, 7 Transaction (income) costs The Company expenses costs net of any gains directly attributable to business acquisitions and classifies these items as transaction (income) costs. These items include among other things, legal fees to complete the acquisition, financial advisor and due diligence costs, and transaction related compensation. These items are recognized as incurred. Earnings (loss) per share Basic earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the weighted average number of common shares outstanding during the year. Diluted earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants, and RSUs and the incremental shares issuable upon conversion of the convertible debentures and similar instruments. Shares of common stock outstanding under the share lending arrangement entered into in conjunction with the TLRY 27 13 In computing diluted earnings (loss) per share, common share equivalents are not three nine February 29, 2024 February 28, 2023 New accounting pronouncements not In August 2023, 2023 05, Business Combination - Joint Venture Formations 805 60 2023 05” 2023 05 June 1, 2026. In October 2023, 2023 06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative, X June 30, 2027, not X not In November 2023, 2023 07, Segment Reporting (Topic 280 2023 07 May 31, 2025. In December 2023, 2023 09, Income Taxes (Topic 740 2023 09 June 01, 2024. New accounting pronouncements recently adopted In October 2021, 2021 08, Business Combinations (Subtopic 805 2021 08” 2021 08 June 1, 2023, not

Note 2 - Inventory

Note 2 - Inventory	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 2. Inventory consisted of the following: February 29, May 31, 2024 2023 Beverage alcohol inventory $ 47,606 $ 27,837 Plants 18,623 10,884 Dried cannabis 102,043 89,801 Cannabis trim — 322 Cannabis derivatives 4,385 9,229 Cannabis vapes 5,250 1,173 Packaging and other inventory items 21,782 19,997 Distribution inventory 33,466 30,144 Wellness inventory 10,984 11,164 Total $ 244,139 $ 200,551

Note 3 - Capital Assets

Note 3 - Capital Assets	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 3. Capital assets consisted of the following: February 29, May 31, 2024 2023 Land $ 45,681 $ 30,635 Production facility 388,234 344,627 Equipment 253,422 185,422 Leasehold improvement 9,379 7,753 Finance lease, right-of-use assets 56,225 — Construction in progress 10,907 8,048 $ 763,848 $ 576,485 Less: accumulated amortization (185,065 ) (146,818 ) Total $ 578,783 $ 429,667 Assets held for sale consisted of the following: February 29, May 31, 2024 2023 Land $ 1,380 $ — Production facility 20,821 — Equipment 6,437 — $ 28,638 $ — On June 22, 2023, 7 May 31, 2024. During the three February 29, 2024, twelve February 29, 2024.

Note 4 - Leases

Note 4 - Leases	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Leases Disclosure [Text Block]	Note 4. The table below presents the lease-related assets and liabilities recorded on the balance sheet. February 29, May 31, Classification on Balance Sheet 2024 2023 Assets Finance lease, right-of-use assets Capital assets $ 56,225 $ — Operating lease, right-of-use assets Operating lease, right-of-use assets 17,453 5,941 Total right-of-use asset $ 73,678 $ 5,941 Liabilities Current: Current portion of finance lease liabilities Current portion of lease liabilities $ 1,370 $ — Current portion of operating lease liabilities Current portion of lease liabilities 4,054 2,423 Non-current: Finance lease liabilities Lease liabilities 55,674 — Operating lease liabilities Lease liabilities 17,554 7,936 Total lease liabilities $ 78,652 $ 10,359 The following table presents the future undiscounted payment associated with lease liabilities as of February 29, 2024 Operating Finance leases leases 2024 $ 1,635 $ 1,261 2025 5,715 5,043 2026 5,361 5,043 2027 4,768 5,043 Thereafter 10,161 85,336 Total minimum lease payments $ 27,640 $ 101,726 Imputed interest (6,032 ) (44,682 ) Obligations recognized $ 21,608 $ 57,044

Note 5 - Intangible Assets

Note 5 - Intangible Assets	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 5. Intangible assets consisted of the following items: February 29, May 31, 2024 2023 Customer relationships & distribution channel $ 617,143 $ 614,062 Licenses, permits & applications 368,649 366,793 Non-compete agreements 12,422 12,394 Intellectual property, trademarks, knowhow & brands 594,441 583,468 1,592,655 $ 1,576,717 Less: accumulated amortization (246,706 ) (187,088 ) Less: impairments (415,844 ) (415,844 ) Total $ 930,105 $ 973,785 Included in licenses, permits & applications was $182,851 of indefinite-lived intangible assets as of February 29, 2024 May 31, 2023 Expected future amortization expense for intangible assets as of February 29, 2024 Amortization 2024 (remaining three months) $ 18,359 2025 73,439 2026 73,439 2027 73,439 2028 73,439 Thereafter 435,139 Total $ 747,254

Note 6 - Goodwill

Note 6 - Goodwill	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Goodwill Disclosure [Text Block]	Note 6. The following table shows the carrying amount of goodwill by reporting units: February 29, May 31, Reporting Unit 2024 2023 Cannabis $ 2,640,669 $ 2,640,669 Distribution 4,458 4,458 Beverage alcohol 120,802 120,802 Wellness 77,470 77,470 Effect of foreign exchange 8,664 7,875 Impairments (842,431 ) (842,431 ) Total $ 2,009,632 $ 2,008,843

Note 7 - Business Acquisitions

Note 7 - Business Acquisitions	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Business Combination Disclosure [Text Block]	Note 7. Business a cquisitions Acquisition of Montauk Brewing Company, Inc. On November 7, 2022, December 31, 2025, 25 The table below summarizes the fair value of the assets acquired and liabilities assumed at the acquisition date. Amount Consideration Cash $ 28,701 Shares 6,422 Contingent consideration 10,245 Net assets acquired Current assets Cash and cash equivalents 1,983 Accounts receivable 1,116 Prepaids and other current assets 467 Inventory 1,570 Long-term assets Capital assets 420 Customer relationships ( 15 18,540 Intellectual property, trademarks & brands ( 15 13,650 Goodwill 17,803 Total assets 55,549 Current liabilities Accounts payable and accrued liabilities 1,580 Long-term liabilities Deferred tax liability 4,851 Other liabilities 3,750 Total liabilities 10,181 Total net assets acquired $ 45,368 In the event that the Montauk acquisition had occurred on June 1, 2022, three nine February 28, 2023, three nine February 28, 2023, not Acquisition of HEXO Corp. On June 22, 2023, 3 The Company is in the process of assessing the fair value of the net assets acquired and, as a result, the fair value may Amount Consideration Shares $ 63,927 Settlement of convertible notes receivable 28,720 Warrants assumed 47 Estimated fair value of HEXO stock-based compensation 1,188 Net assets acquired Current assets Cash and cash equivalents 14,634 Restricted cash 1,656 Accounts receivable 7,855 Asset held for sale 755 Prepaids and other current assets 2,709 Inventory 25,947 Long-term assets Prepaid expenses 8,384 Capital assets 70,634 Intellectual property, trademarks & brands ( 15 2,680 Interest in equity investee 3,145 Total assets 138,399 Current liabilities Accounts payable and accrued liabilities 44,517 Total liabilities 44,517 Total net assets acquired $ 93,882 Included in accounts payable and accrued liabilities was $12,253 of litigation settlement accruals as of June 22, 2023. In the event the HEXO Acquisition had occurred on June 1, 2022, $nil three nine February 29, 2024, three nine February 28, 2023, $nil three nine February 29, 2024, three nine February 28, 2023, not Acquisition of Truss Beverage Co. On August 3, 2023, not CAD$100 three February 29, 2024, November 30, 2023, not The Company is in the process of assessing the fair value of the net assets acquired and, as a result, the fair value of the net assets acquired may Amount Consideration Cash consideration $ 74 Investment in equity investees 3,145 Contingent consideration 4,181 Net assets acquired Current assets Cash and cash equivalents 6,739 Accounts receivable 1,038 Prepaids and other current assets 78 Inventory 2,573 Asset held for sale 2,960 Long-term assets Intangible assets 296 Total assets 13,684 Current liabilities Accounts payable and accrued liabilities 5,408 Other liabilities 876 Total liabilities 6,284 Total net assets acquired 7,400 In the event that the Truss acquisition had occurred on June 1, 2022 $nil three nine February 29, 2024, three nine February 28, 2023, $nil three nine February 29, 2024, three nine February 28, 2023, not Acquisition of Craft Beverage Business Portfolio On September 29, 2023, eight 10 12 , The Company is in the process of assessing the fair value of the net assets acquired and, as a result, the fair value may Amount Consideration Cash consideration $ 83,658 Net assets acquired Current assets Cash and cash equivalents 77 Inventory 22,493 Prepaids and other current assets 573 Long-term assets Capital assets 62,614 Finance lease, right-of-use assets 45,496 Operating lease, right-of-use assets 7,677 Other assets 108 Total assets 139,038 Current liabilities Accounts payable and accrued liabilities 2,206 Current portion of finance lease liabilities 1,031 Current portion of operating lease liabilities 1,408 Long - term liabilities Finance lease liabilities 44,465 Operating lease liabilities 6,270 Total liabilities 55,380 Total net assets acquired 83,658 In the event that the Craft Acquisition had occurred on June 1, 2022, $nil three nine February 29, 2024, three nine February 28, 2023, $nil three nine February 29, 2024, three nine February 28, 2023, not

Note 8 - Convertible Notes Rece

Note 8 - Convertible Notes Receivable	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	Note 8. Convertible notes receivable is comprised of the following: February 29, May 31, 2024 2023 HEXO Convertible Note $ — $ 28,720 MedMen Convertible Note 32,000 74,681 Total convertible notes receivable 32,000 103,401 Deduct - current portion — — Total convertible notes receivable, non current portion $ 32,000 $ 103,401 HEXO Convertible Note On June 22, 2023, 7 MedMen Convertible Note On August 31, 2021, August 17, 2028, During the three February 29, 2024, January 23, 2024 3.50%; nil; nil; 60%; The Company did not not three nine February 29, 2024

Note 9 - Long Term Investments

Note 9 - Long Term Investments	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Investment [Text Block]	Note 9. Long term investments consisted of the following: February 29, May 31, 2024 2023 Equity investments measured at fair value $ 2,558 $ 2,144 Equity investments under measurement alternative 5,500 5,651 Total $ 8,058 $ 7,795

Note 10 - Bank Indebtedness

Note 10 - Bank Indebtedness	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Short-Term Debt [Text Block]	Note 10. Aphria Inc., a subsidiary of the Company, has an operating line of credit in the amount of C$1,000, February 29, 2024 not 265 CC Pharma GmbH, a subsidiary of the Company, has two €7,000 €500 February 29, 2024 €7,434 €7,500. €7,000 €500 American Beverage Crafts Group Inc. ("ABC Group"), formerly known as Four Twenty Corporation, a subsidiary of the Company, has a revolving credit facility of $30,000, which bears interest at SOFR plus an applicable margin. As of February 29, 2024

Note 11 - Accounts Payable and

Note 11 - Accounts Payable and Accrued Liabilities	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 11. Accounts payable and accrued liabilities are comprised of: February 29, May 31, 2024 2023 Trade payables $ 90,163 $ 70,819 Accrued liabilities 70,744 48,394 Litigation accrual 25,153 25,000 Accrued payroll and employment related taxes 14,993 18,772 Income taxes payable 1,438 14,934 Accrued interest 3,202 8,102 Sales taxes payable 4,070 4,661 Total $ 209,763 $ 190,682

Note 12 - Long-term Debt

Note 12 - Long-term Debt	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Long-Term Debt [Text Block]	Note 12. The following table sets forth the net carrying amount of long-term debt instruments: February 29, May 31, 2024 2023 Credit facility - C$ 66,000 3 10 November 2025 $ 41,440 $ 45,260 Term loan - C$ 25,000 1.00 5 15 181 July 2033 10,541 10,959 Term loan - C$ 25,000 1.00 5 15 196 July 2033 12,765 13,092 Term loan - C$ 1,250 1.50 5 10 12 August 2026 288 346 Mortgage payable - C$ 3,750 1.50 5 20 23 August 2026 2,122 2,104 Term loan ‐ € 5,000 2.15 5 250 December 2023 — 803 Term loan ‐ € 1,200 4.26 1 100 December 2023 — 755 Term loan ‐ € 1,500 2.00 5 94 April 2025 520 819 Term loan ‐ € 3,500 4.59 5 52 August 2028 3,326 1,706 Mortgage payable - $ 22,635 1.5 10 57 October 2030 20,225 20,863 Term loan - $ 90,000 5 875 1,750 June 2028 87,750 65,000 Carrying amount of long-term debt 178,977 161,707 Unamortized financing fees (978 ) (738 ) Net carrying amount 177,999 160,969 Less principal portion included in current liabilities (12,351 ) (24,080 ) Total noncurrent portion of long-term debt $ 165,648 $ 136,889 During the quarter ended August 31, 2023, June 30, 2028 June 30, 2023. September 29, 2023 7 Business cquisitions

Note 13 - Convertible Debenture

Note 13 - Convertible Debentures Payable	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Convertible Debentures [Text Block]	Note 13. The following table sets forth the net carrying amount of the convertible debentures payable: February 29, May 31, 2024 2023 5.20 $ 126,587 $ 100,476 HTI Convertible Note — 47,834 5.25 83,351 120,568 5.00 — 126,544 Total 209,938 395,422 Deduct - current portion 83,351 174,378 Total convertible debentures payable, non current portion $ 126,587 $ 221,044 TLRY 27 February 29, May 31, 2024 2023 5.20 $ 172,500 $ 150,000 Unamortized discount (45,913 ) (49,524 ) Net carrying amount $ 126,587 $ 100,476 The TLRY 27 May 30, 2023 June 9, 2023 27 27 June 15 December 15 June 15, 2027, 27 not 23 24, 27 second June 15, 2027. 27 The TLRY 27 not June 20, 2025 may 27 27 may 27 27 not During the three nine February 29, 2024 no HTI Convertible Note February 29, May 31, 2024 2023 4.00 $ — $ 50,000 Unamortized discount — (2,166 ) Net carrying amount $ — $ 47,834 On July 12, 2022, September 1, 2023. August 31, 2023, 15 APHA 24 February 29, May 31, 2024 2023 5.25 $ 350,000 $ 350,000 Debt settlement (263,970 ) (213,260 ) Fair value adjustment (2,679 ) (16,172 ) Net carrying amount $ 83,351 $ 120,568 The APHA 24 April 2019, June 1 December 1 June 1, 2024, 24 24 not 27 Holders of the APHA 24 may $1 December 1, 2023 June 1, 2024. may The Company may 24, 24 The Company elected the fair value option under ASC 825 Financial Instruments 24. 24 During the three February 29, 2024, 24 The overall change in fair value of APHA 24 nine February 29, 2024 There was $86,030 principal outstanding as at February 29, 2024 May 31, 2023. 27 During the three nine February 29, 2024 TLRY 23 February 29, May 31, 2024 2023 5.00 $ — $ 277,856 Principal amount paid — (150,526 ) Unamortized discount — (786 ) Net carrying amount $ — $ 126,544 The TLRY 23 April 1 October 1 September 12, 2023, 23 23 24 After cancellation, the outstanding principal balance of the TLRY 23 October 2, 2023, 23 During the three nine February 29, 2024 $nil

Note 14 - Warrant Liability

Note 14 - Warrant Liability	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Warrants [Text Block]	Note 14. As of February 29, 2024 May 31, 2023, September 17, 2025. one The warrants contain anti-dilution price protection features, which adjust the exercise price of the warrants if the Company subsequently issues common stock at a price lower than the exercise price of the warrants. In the event additional warrants or convertible debt are issued with a lower and/or variable exercise price, the exercise price of the warrants will be adjusted accordingly. During the nine February 29, 2024 may may 3 9 1933 not may may may not The Company estimated the fair value of warrants outstanding at February 29, 2024 3 Expected volatility is based on both historical and implied volatility of the Company’s common stock.

Note 15 - Stockholders' Equity

Note 15 - Stockholders' Equity	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Equity [Text Block]	Note 15. Issued and outstanding As of February 29, 2024 nil During the nine February 29, 2024 a) 39,705,962 shares in connection with the HEXO Acquisition, see Note 7 b) 865,426 shares to settle a contractual change of control severance obligations in the aggregate amount of $1,500 incurred in connection with the HEXO Acquisition. c) 18,632,126 shares to settle dividends payable to the non-controlling shareholders of 1974568 d) 1,032,616 shares for the settlement of the HTI Convertible Note payable see Note 13 e) 17,148,541 shares to HTI Investments MA LLC pursuant to the terms of a $50.0 million convertible promissory note originally issued by Tilray to HTI on July 12, 2022 f) 1,573,152 shares to settle HEXO-based litigation judgement obtained by MediPharm Labs Inc. in 2022. g) 7,000,000 shares to repurchase $20,000 of its TLRY 23 h) 27,228,252 shares to repurchase $50,710 of its APHA 24 i) 4,186,523 shares in connection with the exercise of previously awarded stock-based compensation awards. The Company maintains stock-based compensation plans as disclosed in our Annual Financial Statements. For the three nine February 29, 2024 three nine February 28, 2023, During the nine February 29, 2024 February 28, 2023 - not For the three months ended For the nine months ended February 29, February 28, February 29, February 28, 2024 2023 2024 2023 Stock options $ — $ 20 $ — $ 644 RSUs 8,059 9,610 24,517 29,122 Total $ 8,059 $ 9,630 $ 24,517 $ 29,766

Note 16 - Accumulated Other Com

Note 16 - Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Comprehensive Income (Loss) Note [Text Block]	Note 16. Accumulated other comprehensive loss includes the following components: Unrealized Foreign loss on currency convertible translation notes gain (loss) receivables Total Balance May 31, 2022 $ 54,413 $ (75,177 ) $ (20,764 ) Other comprehensive loss (56,443 ) (2,525 ) (58,968 ) Balance August 31, 2022 $ (2,030 ) $ (77,702 ) $ (79,732 ) Other comprehensive loss (24,080 ) (17,643 ) (41,723 ) Balance November 30, 2022 $ (26,110 ) $ (95,345 ) $ (121,455 ) Other comprehensive (loss) reversal (16,838 ) 95,345 78,507 Balance February 28, 2023 $ (42,948 ) $ — $ (42,948 ) Balance May 31, 2023 $ (46,610 ) $ — $ (46,610 ) Other comprehensive loss 3,049 — 3,049 Balance August 31, 2023 $ (43,561 ) $ — $ (43,561 ) Other comprehensive loss 5,194 — 5,194 Balance November 30, 2023 $ (38,367 ) $ — $ (38,367 ) Other comprehensive loss (4,820 ) — (4,820 ) Balance February 29, 2024 $ (43,187 ) $ — $ (43,187 )

Note 17 - Non-controlling Inter

Note 17 - Non-controlling Interests	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 17. The following tables summarize the information relating to the Company’s subsidiaries, SH Acquisition (68%), CC Pharma Nordic ApS (75%), Aphria Diamond (51%), and ColCanna S.A.S. (90%) before intercompany eliminations. Summary of balance sheet information of the entities in which there is a non-controlling interest as of February 29, 2024 SH CC Pharma Aphria ColCanna February 29, Acquisition Nordic ApS Diamond S.A.S. 2024 Current assets $ — $ 31 $ 81,541 $ 191 $ 81,763 Non-current assets 32,000 — 129,067 3,719 164,786 Current liabilities — (14 ) (129,422 ) (6,786 ) (136,222 ) Non-current liabilities — — (48,218 ) (1,458 ) (49,676 ) Net assets $ 32,000 $ 17 $ 32,968 $ (4,334 ) $ 60,651 Summary of balance sheet information of the entities there is a non-controlling interest as of May 31, 2023 SH CC Pharma Aphria ColCanna May 31, Acquisition Nordic ApS Diamond S.A.S. 2023 Current assets $ — $ 114 $ 127,689 $ 224 $ 128,027 Non-current assets 74,681 — 135,085 3,307 213,073 Current liabilities — (1,166 ) (142,554 ) (6,697 ) (150,417 ) Non-current liabilities — — (53,197 ) (1,428 ) (54,625 ) Net assets $ 74,681 $ (1,052 ) $ 67,023 $ (4,594 ) $ 136,058 Summary of income statement information of the entities in which there is a non-controlling interest for the nine February 29, 2024 SH CC Pharma Aphria ColCanna February 29, Acquisition Nordic ApS Diamond S.A.S. 2024 Revenue $ — $ — $ 76,541 $ — $ 76,541 Total expenses 42,681 (1,078 ) 47,541 (594 ) 88,550 Net (loss) income (42,681 ) 1,078 29,000 594 (12,009 ) Other comprehensive (loss) income — (9 ) 646 (334 ) 303 Net comprehensive (loss) income $ (42,681 ) $ 1,069 $ 29,646 $ 260 $ (11,706 ) Non-controlling interest % 32 % 25 % 49 % 10 % NA Comprehensive (loss) income attributable to NCI (13,658 ) 267 14,527 26 1,162 Additional income attributable to NCI — — 5,336 — 5,336 Net comprehensive (loss) income attributable to NCI $ (13,658 ) $ 267 $ 19,863 $ 26 $ 6,498 Summary of income statement information of the entities in which there is a non-controlling interest for the nine February 28, 2023: SH CC Pharma Aphria ColCanna February 28, Acquisition Nordic ApS Diamond S.A.S. 2023 Revenue $ — $ 126 $ 98,960 $ — $ 99,086 Total expenses 107,297 659 54,285 91,026 253,267 Net (loss) income (107,297 ) (533 ) 44,675 (91,026 ) (154,181 ) Other comprehensive (loss) income 70,778 (13 ) (707 ) 373 70,431 Net comprehensive (loss) income $ (36,519 ) $ (546 ) $ 43,968 $ (90,653 ) $ (83,750 ) Non-controlling interest % 32 % 25 % 49 % 10 % NA Comprehensive (loss) income attributable to NCI (11,686 ) (137 ) 21,544 (9,065 ) 656 Additional income attributable to NCI — — 8,968 — 8,968 Net comprehensive (loss) income attributable to NCI $ (11,686 ) $ (137 ) $ 30,512 $ (9,065 ) $ 9,624 On January 5, 2024, 1974568 September 1, 2023, June 1, 2023,

Note 18 - Income Taxes

Note 18 - Income Taxes	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 18. The determination of the Company’s overall effective tax rate requires significant judgment, the use of estimates, and the interpretation and application of complex tax laws. The effective tax rate reflects the income earned and taxed in various United States federal, state, and foreign jurisdictions. Tax law changes, increases, and decreases in temporary and permanent differences between book and tax items, valuation allowances against the deferred tax assets, stock compensation, and the Company’s change in income in each jurisdiction all affect the overall effective tax rate. It is the Company’s practice to recognize interest and penalties related to uncertain tax positions in income tax expense. The Company reported income tax (recovery) expense of $(2,871) and $1,013 for the three nine February 29, 2024 three nine February 28, 2023 no

Note 19 - Commitments and Conti

Note 19 - Commitments and Contingencies	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 19. Purchase and other commitments The Company has payments on long-term debt, refer to Note 12 13 Total 2024 2025 2026 2027 Thereafter Long-term debt repayment $ 178,977 $ 12,535 $ 44,319 $ 8,973 $ 10,335 $ 102,815 Convertible debentures payable 258,530 86,030 — — 172,500 — Material purchase obligations 49,159 21,587 27,572 — — — Construction commitments 822 822 — — — — Total $ 487,488 $ 120,974 $ 71,891 $ 8,973 $ 182,835 $ 102,815 Legal proceedings In the ordinary course of business, we are at times subject to various legal proceedings and disputes, including the proceedings specifically discussed below. We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our consolidated financial statements. These legal reserves may not not not not may There have been no 10 May 31, 2023 420 Investments Ltd. Litigation On February 21, 2020, 420 “420 August 2019, 420 “420 420 420 February 2020, 420 420 420 no 420 C$110,000, C$20,000 no In February 2023, C$7,000 420 August 28, 2019. March 2020, 420 February 8, 2024, C$7,000 22 C$2,800 420 Cannfections Group Inc. / High Park Farms Ltd. (Canada, Commercial Arbitration) . On December 2, 2022 2019 C$27,500. November 2023. March 5, 2024, C$19,950 not On April 5, 2024, $4,638 three February 29, 2024. not 24 Summary of litigation accruals As described in Note 11 February 29, 2024 May 31, 2023 - $ nine February 29, 2024, nine February 29, 2024 not

Note 20 - Net Revenue

Note 20 - Net Revenue	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 20. The Company reports its net revenue in four Net revenue is comprised of: For the three months ended For the nine months ended February 29, February 28, February 29, February 28, 2024 2023 2024 2023 Beverage alcohol revenue $ 58,247 $ 21,941 $ 133,237 $ 67,209 Beverage alcohol excise taxes (3,559 ) (1,301 ) (7,882 ) (4,520 ) Net beverage alcohol revenue 54,688 20,640 125,355 62,689 Cannabis revenue 85,236 61,118 276,676 203,503 Cannabis excise taxes (21,804 ) (13,569 ) (75,797 ) (47,486 ) Net cannabis revenue 63,432 47,549 200,879 156,017 Distribution revenue 56,794 65,385 193,174 186,158 Wellness revenue 13,426 12,015 39,652 38,072 Total $ 188,340 $ 145,589 $ 559,060 $ 442,936

Note 21 - Cost of Goods Sold

Note 21 - Cost of Goods Sold	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Cost of Goods Sold [Text Block]	Note 21. Cost of goods sold is comprised of: For the three months ended For the nine months ended February 29, February 28, February 29, February 28, 2024 2023 2024 2023 Beverage alcohol costs $ 35,836 $ 10,663 $ 77,615 $ 32,932 Cannabis costs 42,518 80,362 139,507 137,800 Distribution costs 51,231 57,964 172,846 165,443 Wellness costs 9,359 8,299 28,091 26,964 Total $ 138,944 $ 157,288 $ 418,059 $ 363,139

Note 22 - General and Administr

Note 22 - General and Administrative Expenses	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
General and Administrative Expenses [Text Block]	Note 22. General and administrative expenses are comprised of: For the three months ended For the nine months ended February 29, February 28, February 29, February 28, 2024 2023 2024 2023 Executive compensation $ 1,585 $ 2,754 $ 4,757 $ 9,359 Office and general 4,190 6,799 20,423 20,011 Salaries and wages 19,588 13,621 52,310 38,407 Stock-based compensation 8,059 9,630 24,517 29,766 Insurance 3,569 3,159 9,917 8,588 Professional fees 656 1,165 4,658 5,385 (Gain) loss on sale of capital assets 23 (15 ) 3 (2 ) Travel and accommodation 1,246 1,104 3,727 3,484 Rent 1,024 782 3,457 2,387 Total $ 39,940 $ 38,999 $ 123,769 $ 117,385 Included in office and general is $4,440 ( C$6,000 19 420

Note 23 - Restructuring Charges

Note 23 - Restructuring Charges	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	Note 23. In connection with the execution of our acquisition strategy and strategic transactions, the Company has incurred restructuring and exit costs associated with the integration efforts of these non-recurring transactions. The Company recognized $5,178 and $8,748 of restructuring charges for the three nine February 29, 2024 February 29, 2024 Within the Cannabis reporting unit, three 24 18 nine February 29, 2024 Within the distribution reporting unit, the Company continued to execute on a cost optimization plan during the three months ended February 29, 2024. nine February 29, 2024 For the three nine February 28, 2023, February 28, 2023, not nine February 29, 2024

Note 24 - Non-operating Income

Note 24 - Non-operating Income (Expense)	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Other Nonoperating Income and Expense [Text Block]	Note 24. Non-operating income (expense) is comprised of: For the three months ended For the nine months ended February 29, February 28, February 29, February 28, 2024 2023 2024 2023 Change in fair value of convertible debenture payable $ (6,311 ) $ 207 $ (12,352 ) $ (20,375 ) Change in fair value of warrant liability 586 5,256 (1,365 ) 6,841 Foreign exchange loss (gain) (3,302 ) (1,955 ) 1,941 (26,621 ) Loss on long-term investments 33 (925 ) 383 (2,529 ) Other non-operating (losses) gains, net (8,245 ) (1,370 ) (9,427 ) (7,545 ) Total $ (17,239 ) $ 1,213 $ (20,820 ) $ (50,229 ) Included in other non-operating (losses) gains, net for the three nine February 29, 2024 15 19

Note 25 - Fair Value Measuremen

Note 25 - Fair Value Measurements	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 25. Fair value measurements Financial instruments The Company has classified its financial instruments as described in Note 3 The carrying values of marketable securities, accounts receivable, bank indebtedness and accounts payable and accrued liabilities approximate their fair values due to their short periods to maturity. At February 29, 2024 May 31, 2023 The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of February 29, 2024 May 31, 2023 February 29, Level 1 Level 2 Level 3 2024 Financial assets Cash and cash equivalents $ 146,253 $ — $ — $ 146,253 Marketable securities 79,605 — — 79,605 Convertible notes receivable — — 32,000 32,000 Equity investments measured at fair value 1,104 1,454 5,500 8,058 Financial liabilities Warrant liability — — (3,182 ) (3,182 ) Contingent consideration — — (14,000 ) (14,000 ) APHA 24 Convertible debenture — — (83,351 ) (83,351 ) Total recurring fair value measurements $ 226,962 $ 1,454 $ (63,033 ) $ 165,383 May 31, Level 1 Level 2 Level 3 2023 Financial assets Cash and cash equivalents $ 206,632 $ — $ — $ 206,632 Marketable Securities 241,897 — — 241,897 Convertible notes receivable — — 103,401 103,401 Equity investments measured at fair value 1,056 1,088 5,651 7,795 Financial liabilities Warrant liability — — (1,817 ) (1,817 ) Contingent consideration — — (27,107 ) (27,107 ) APHA 24 Convertible debenture — — (120,568 ) (120,568 ) Total recurring fair value measurements $ 449,585 $ 1,088 $ (40,440 ) $ 410,233 The Company’s financial assets and liabilities required to be measured on a recurring basis are its convertible notes receivable, equity investments measured at fair value, convertible debentures measured at fair value, acquisition-related contingent consideration, and warrant liability. Convertible notes receivable and long-term investments are recorded at fair value. The estimated fair value is determined using the Black Scholes option pricing model, probability of legalization and is classified as Level 3. Convertible debentures payable are recorded at fair value when elected or required under US GAAP. Specifically, the APHA 24 3. Certain equity investments recorded at fair value have quoted prices in active markets for identical assets and are classified as Level 1. 2 3. The warrants associated with the warrant liability are classified as Level 3 The contingent consideration from the acquisition of Montauk due in December 2025, 3. nine February 29, 2024 not The balances of assets and liabilities categorized within Level 3 APHA 24 Convertible Equity Warrant Contingent Convertible notes receivable Investments Liability Consideration Debt Balance, May 31, 2023 $ 103,401 $ 5,651 $ (1,817 ) $ (27,107 ) $ (120,568 ) Additions/(Repayments) — — — (4,181 ) 50,710 Redemption (28,720 ) — — 760 — Unrealized gain (loss) on fair value — (151 ) (1,365 ) 16,528 (13,493 ) Impairments (42,681 ) — — — — Balance, February 29, 2024 $ 32,000 $ 5,500 $ (3,182 ) $ (14,000 ) $ (83,351 ) The unrealized gain (loss) on fair value for the convertible debenture, the warrant liability, contingent consideration, and debt securities classified under available-for-sale method is recognized in the consolidated statements of loss and comprehensive loss using the following inputs: Significant Valuation unobservable Financial asset / financial liability technique input Inputs APHA Convertible debentures Black-Scholes Volatility, 50% expected life (in years) 0.3 Warrant liability Black-Scholes Volatility, 50% expected life (in years) 1.6 Contingent consideration Discounted cash flows Discount rate, 11 % achievement 95% Items measured at fair value on a non-recurring basis The Company's prepaids and other current assets, long lived assets, including property and equipment, goodwill and intangible assets are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized. Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There have been no

Note 26 - Segment Reporting

Note 26 - Segment Reporting	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 26. Segment reporting Information reported to the Chief Operating Decision Maker (“CODM”) for the purpose of resource allocation and assessment of segment performance focuses on the nature of the operations. The Company operates in four 1 2 3 4 Operating segments have not no not Segment gross profit from external customers: For the three months ended For the nine months ended February 29, February 28, February 29, February 28, 2024 2023 2024 2023 Beverage alcohol Net beverage alcohol revenue $ 54,688 $ 20,640 $ 125,355 $ 62,689 Beverage alcohol costs 35,836 10,663 77,615 32,932 Beverage alcohol gross profit 18,852 9,977 47,740 29,757 Cannabis Net cannabis revenue 63,432 47,549 200,879 156,017 Cannabis costs 42,518 80,362 139,507 137,800 Cannabis gross profit (loss) 20,914 (32,813 ) 61,372 18,217 Distribution Distribution revenue 56,794 65,385 193,174 186,158 Distribution costs 51,231 57,964 172,846 165,443 Distribution gross profit 5,563 7,421 20,328 20,715 Wellness Wellness revenue 13,426 12,015 39,652 38,072 Wellness costs 9,359 8,299 28,091 26,964 Wellness gross profit $ 4,067 $ 3,716 $ 11,561 $ 11,108 Channels of Cannabis revenue were as follows: For the three months ended For the nine months ended February 29, February 28, February 29, February 28, 2024 2023 2024 2023 Revenue from Canadian medical cannabis $ 6,363 $ 6,035 $ 18,793 $ 18,920 Revenue from Canadian adult-use cannabis 62,107 45,318 205,350 156,063 Revenue from wholesale cannabis 2,764 58 12,348 686 Revenue from international cannabis 14,002 9,707 40,185 27,834 Less excise taxes (21,804 ) (13,569 ) (75,797 ) (47,486 ) Total $ 63,432 $ 47,549 $ 200,879 $ 156,017 On July 12, 2022, 8 13 June 22, 2023, 7 Included in revenue from Canadian adult-use cannabis is $nil three nine February 29, 2024 Geographic net revenue: For the three months ended For the nine months ended February 29, February 28, February 29, February 28, 2024 2023 2024 2023 North America $ 117,524 $ 70,463 $ 325,664 $ 228,866 EMEA 67,143 71,111 222,139 199,867 Rest of World 3,673 4,015 11,257 14,203 Total $ 188,340 $ 145,589 $ 559,060 $ 442,936 Geographic capital assets: February 29, May 31, 2024 2023 North America $ 473,779 $ 319,173 EMEA 101,271 107,131 Rest of World 3,733 3,363 Total $ 578,783 $ 429,667 Major customers are defined as customers that are materially significant to the Company’s annual revenues. For the three nine February 29, 2024 2023 no

Note 27 - Subsequent Events

Note 27 - Subsequent Events	9 Months Ended
	Feb. 29, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	Note 27. Subsequent Events On April 9, 2024, 24

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
	Feb. 29, 2024	Feb. 29, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]		5. Other 2024 On April 4, 2024, 2018 “2018 “2024 2024 2018 2024 The percentage of the 2024 June 1, 2023 May 31, 2026 ( 2024 May 31, 2026) 2018 not 2024 may 0% 100% If the executive officer’s Continuous Service terminates for any reason other than: (i) without Cause (as defined in the 2018 3 2018 2018 2024 3 2024 2024 100% 2024 100% The foregoing description is only a summary of the terms of the 2024 2024 10 February 29, 2024. Aphria Diamond Amalgamation and Amendment to Bank of Montreal Credit Facility On March 14, 2024, 1974568 51% November 28, 2022, APHA 24 On April 9, 2024, $41.9 24 25,000,000 4 2 1933, not No no
Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Feb. 29, 2024
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Basis of consolidation Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of all subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases. All intercompany balances and transactions have been eliminated on consolidation. A complete list of our subsidiaries that existed as of our most recent fiscal year end is included in the Annual Report, except for the entities acquired within Note 7 nine February 29, 2024
Marketable Securities, Policy [Policy Text Block]	Marketable securities We classify term deposits and other investments that have maturities of greater than three one
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted cash We classify cash that is legally or contractually restricted as to withdrawal or usage as restricted cash. As of February 29, 2024 May 31, 2023, $nil six November 31, 2023, 7 three February 29, 2024,
Assets Held-for-Sale, Policy [Policy Text Block]	Assets held for sale We classify capital assets that are available for immediate sale in their present condition, which the Company has approved the action or plan to sell, and the sales is probable within one February 29, 2024 3 When there are changes in circumstances that were previously considered unlikely to occur, and it is decided not not
Investment, Policy [Policy Text Block]	Long-term investments Investments in equity securities of entities over which the Company does not Investments in entities over which the Company does not may not 820 Fair Value Measurement
Financing Receivable [Policy Text Block]	Convertible notes receivable Convertible notes receivable includes various investments in which the Company has the right, or potential right to convert the indenture into common stock of the investee and are classified as available-for-sale and are recorded at fair value. Unrealized gains and losses during the year, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders' equity until realized. We use judgement to assess convertible notes receivables for impairment at each measurement date. Convertible notes receivables are impaired when a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the consolidated statements of loss and comprehensive loss and a new cost basis for the investment is established. We also evaluate whether there is a plan to sell the security, or it is more likely than not
Revenue [Policy Text Block]	Revenue Revenue is recognized when the control of the promised goods or services, through performance obligation, is transferred or provided to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for the performance obligations. Excise taxes remitted to tax authorities are government-imposed excise taxes on cannabis and beer. Excise taxes are recorded as a reduction of sales in net revenue in the consolidated statements of loss and comprehensive loss and recognized as a current liability within accounts payable and accrued liabilities on the consolidated balance sheets, with the liability subsequently reduced when the taxes are remitted to the tax authority. In addition, amounts disclosed as net revenue are net of excise taxes, sales tax, duty tax, allowances, discounts and rebates. In determining the transaction price for the sale of goods or services, the Company considers the effects of variable consideration and the existence of significant financing components, if any. We may may may On July 12, 2022, 26 June 22, 2023, 7
Transaction Costs Policy [Policy Text Block]	Transaction (income) costs The Company expenses costs net of any gains directly attributable to business acquisitions and classifies these items as transaction (income) costs. These items include among other things, legal fees to complete the acquisition, financial advisor and due diligence costs, and transaction related compensation. These items are recognized as incurred.
Earnings Per Share, Policy [Policy Text Block]	Earnings (loss) per share Basic earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the weighted average number of common shares outstanding during the year. Diluted earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants, and RSUs and the incremental shares issuable upon conversion of the convertible debentures and similar instruments. Shares of common stock outstanding under the share lending arrangement entered into in conjunction with the TLRY 27 13 In computing diluted earnings (loss) per share, common share equivalents are not three nine February 29, 2024 February 28, 2023
New Accounting Pronouncements, Policy [Policy Text Block]	New accounting pronouncements not In August 2023, 2023 05, Business Combination - Joint Venture Formations 805 60 2023 05” 2023 05 June 1, 2026. In October 2023, 2023 06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative, X June 30, 2027, not X not In November 2023, 2023 07, Segment Reporting (Topic 280 2023 07 May 31, 2025. In December 2023, 2023 09, Income Taxes (Topic 740 2023 09 June 01, 2024. New accounting pronouncements recently adopted In October 2021, 2021 08, Business Combinations (Subtopic 805 2021 08” 2021 08 June 1, 2023, not

Note 2 - Inventory (Tables)

Note 2 - Inventory (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	February 29, May 31, 2024 2023 Beverage alcohol inventory $ 47,606 $ 27,837 Plants 18,623 10,884 Dried cannabis 102,043 89,801 Cannabis trim — 322 Cannabis derivatives 4,385 9,229 Cannabis vapes 5,250 1,173 Packaging and other inventory items 21,782 19,997 Distribution inventory 33,466 30,144 Wellness inventory 10,984 11,164 Total $ 244,139 $ 200,551

Note 3 - Capital Assets (Tables

Note 3 - Capital Assets (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	February 29, May 31, 2024 2023 Land $ 45,681 $ 30,635 Production facility 388,234 344,627 Equipment 253,422 185,422 Leasehold improvement 9,379 7,753 Finance lease, right-of-use assets 56,225 — Construction in progress 10,907 8,048 $ 763,848 $ 576,485 Less: accumulated amortization (185,065 ) (146,818 ) Total $ 578,783 $ 429,667
Disclosure of Long-Lived Assets Held-for-Sale [Table Text Block]	February 29, May 31, 2024 2023 Land $ 1,380 $ — Production facility 20,821 — Equipment 6,437 — $ 28,638 $ —

Note 4 - Leases (Tables)

Note 4 - Leases (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Lease Related Assets and Liabilities [Table Text Block]	February 29, May 31, Classification on Balance Sheet 2024 2023 Assets Finance lease, right-of-use assets Capital assets $ 56,225 $ — Operating lease, right-of-use assets Operating lease, right-of-use assets 17,453 5,941 Total right-of-use asset $ 73,678 $ 5,941 Liabilities Current: Current portion of finance lease liabilities Current portion of lease liabilities $ 1,370 $ — Current portion of operating lease liabilities Current portion of lease liabilities 4,054 2,423 Non-current: Finance lease liabilities Lease liabilities 55,674 — Operating lease liabilities Lease liabilities 17,554 7,936 Total lease liabilities $ 78,652 $ 10,359
Lessee, Operating and Finance Lease, Liabilities, to be Paid, Maturity [Table Text Block]	Operating Finance leases leases 2024 $ 1,635 $ 1,261 2025 5,715 5,043 2026 5,361 5,043 2027 4,768 5,043 Thereafter 10,161 85,336 Total minimum lease payments $ 27,640 $ 101,726 Imputed interest (6,032 ) (44,682 ) Obligations recognized $ 21,608 $ 57,044

Note 5 - Intangible Assets (Tab

Note 5 - Intangible Assets (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	February 29, May 31, 2024 2023 Customer relationships & distribution channel $ 617,143 $ 614,062 Licenses, permits & applications 368,649 366,793 Non-compete agreements 12,422 12,394 Intellectual property, trademarks, knowhow & brands 594,441 583,468 1,592,655 $ 1,576,717 Less: accumulated amortization (246,706 ) (187,088 ) Less: impairments (415,844 ) (415,844 ) Total $ 930,105 $ 973,785
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Amortization 2024 (remaining three months) $ 18,359 2025 73,439 2026 73,439 2027 73,439 2028 73,439 Thereafter 435,139 Total $ 747,254

Note 6 - Goodwill (Tables)

Note 6 - Goodwill (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Schedule of Goodwill [Table Text Block]	February 29, May 31, Reporting Unit 2024 2023 Cannabis $ 2,640,669 $ 2,640,669 Distribution 4,458 4,458 Beverage alcohol 120,802 120,802 Wellness 77,470 77,470 Effect of foreign exchange 8,664 7,875 Impairments (842,431 ) (842,431 ) Total $ 2,009,632 $ 2,008,843

Note 7 - Business Acquisitions

Note 7 - Business Acquisitions (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Amount Consideration Cash $ 28,701 Shares 6,422 Contingent consideration 10,245 Net assets acquired Current assets Cash and cash equivalents 1,983 Accounts receivable 1,116 Prepaids and other current assets 467 Inventory 1,570 Long-term assets Capital assets 420 Customer relationships ( 15 18,540 Intellectual property, trademarks & brands ( 15 13,650 Goodwill 17,803 Total assets 55,549 Current liabilities Accounts payable and accrued liabilities 1,580 Long-term liabilities Deferred tax liability 4,851 Other liabilities 3,750 Total liabilities 10,181 Total net assets acquired $ 45,368 Amount Consideration Shares $ 63,927 Settlement of convertible notes receivable 28,720 Warrants assumed 47 Estimated fair value of HEXO stock-based compensation 1,188 Net assets acquired Current assets Cash and cash equivalents 14,634 Restricted cash 1,656 Accounts receivable 7,855 Asset held for sale 755 Prepaids and other current assets 2,709 Inventory 25,947 Long-term assets Prepaid expenses 8,384 Capital assets 70,634 Intellectual property, trademarks & brands ( 15 2,680 Interest in equity investee 3,145 Total assets 138,399 Current liabilities Accounts payable and accrued liabilities 44,517 Total liabilities 44,517 Total net assets acquired $ 93,882 Amount Consideration Cash consideration $ 74 Investment in equity investees 3,145 Contingent consideration 4,181 Net assets acquired Current assets Cash and cash equivalents 6,739 Accounts receivable 1,038 Prepaids and other current assets 78 Inventory 2,573 Asset held for sale 2,960 Long-term assets Intangible assets 296 Total assets 13,684 Current liabilities Accounts payable and accrued liabilities 5,408 Other liabilities 876 Total liabilities 6,284 Total net assets acquired 7,400 Amount Consideration Cash consideration $ 83,658 Net assets acquired Current assets Cash and cash equivalents 77 Inventory 22,493 Prepaids and other current assets 573 Long-term assets Capital assets 62,614 Finance lease, right-of-use assets 45,496 Operating lease, right-of-use assets 7,677 Other assets 108 Total assets 139,038 Current liabilities Accounts payable and accrued liabilities 2,206 Current portion of finance lease liabilities 1,031 Current portion of operating lease liabilities 1,408 Long - term liabilities Finance lease liabilities 44,465 Operating lease liabilities 6,270 Total liabilities 55,380 Total net assets acquired 83,658

Note 8 - Convertible Notes Re_2

Note 8 - Convertible Notes Receivable (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	February 29, May 31, 2024 2023 HEXO Convertible Note $ — $ 28,720 MedMen Convertible Note 32,000 74,681 Total convertible notes receivable 32,000 103,401 Deduct - current portion — — Total convertible notes receivable, non current portion $ 32,000 $ 103,401

Note 9 - Long Term Investments

Note 9 - Long Term Investments (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block]	February 29, May 31, 2024 2023 Equity investments measured at fair value $ 2,558 $ 2,144 Equity investments under measurement alternative 5,500 5,651 Total $ 8,058 $ 7,795

Note 11 - Accounts Payable an_2

Note 11 - Accounts Payable and Accrued Liabilities (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	February 29, May 31, 2024 2023 Trade payables $ 90,163 $ 70,819 Accrued liabilities 70,744 48,394 Litigation accrual 25,153 25,000 Accrued payroll and employment related taxes 14,993 18,772 Income taxes payable 1,438 14,934 Accrued interest 3,202 8,102 Sales taxes payable 4,070 4,661 Total $ 209,763 $ 190,682

Note 12 - Long-term Debt (Table

Note 12 - Long-term Debt (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Schedule of Long-Term Debt Instruments [Table Text Block]	February 29, May 31, 2024 2023 Credit facility - C$ 66,000 3 10 November 2025 $ 41,440 $ 45,260 Term loan - C$ 25,000 1.00 5 15 181 July 2033 10,541 10,959 Term loan - C$ 25,000 1.00 5 15 196 July 2033 12,765 13,092 Term loan - C$ 1,250 1.50 5 10 12 August 2026 288 346 Mortgage payable - C$ 3,750 1.50 5 20 23 August 2026 2,122 2,104 Term loan ‐ € 5,000 2.15 5 250 December 2023 — 803 Term loan ‐ € 1,200 4.26 1 100 December 2023 — 755 Term loan ‐ € 1,500 2.00 5 94 April 2025 520 819 Term loan ‐ € 3,500 4.59 5 52 August 2028 3,326 1,706 Mortgage payable - $ 22,635 1.5 10 57 October 2030 20,225 20,863 Term loan - $ 90,000 5 875 1,750 June 2028 87,750 65,000 Carrying amount of long-term debt 178,977 161,707 Unamortized financing fees (978 ) (738 ) Net carrying amount 177,999 160,969 Less principal portion included in current liabilities (12,351 ) (24,080 ) Total noncurrent portion of long-term debt $ 165,648 $ 136,889

Note 13 - Convertible Debentu_2

Note 13 - Convertible Debentures Payable (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Convertible Debt [Table Text Block]	February 29, May 31, 2024 2023 5.20 $ 126,587 $ 100,476 HTI Convertible Note — 47,834 5.25 83,351 120,568 5.00 — 126,544 Total 209,938 395,422 Deduct - current portion 83,351 174,378 Total convertible debentures payable, non current portion $ 126,587 $ 221,044 February 29, May 31, 2024 2023 5.20 $ 172,500 $ 150,000 Unamortized discount (45,913 ) (49,524 ) Net carrying amount $ 126,587 $ 100,476 February 29, May 31, 2024 2023 4.00 $ — $ 50,000 Unamortized discount — (2,166 ) Net carrying amount $ — $ 47,834 February 29, May 31, 2024 2023 5.25 $ 350,000 $ 350,000 Debt settlement (263,970 ) (213,260 ) Fair value adjustment (2,679 ) (16,172 ) Net carrying amount $ 83,351 $ 120,568 February 29, May 31, 2024 2023 5.00 $ — $ 277,856 Principal amount paid — (150,526 ) Unamortized discount — (786 ) Net carrying amount $ — $ 126,544

Note 15 - Stockholders' Equity

Note 15 - Stockholders' Equity (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	For the three months ended For the nine months ended February 29, February 28, February 29, February 28, 2024 2023 2024 2023 Stock options $ — $ 20 $ — $ 644 RSUs 8,059 9,610 24,517 29,122 Total $ 8,059 $ 9,630 $ 24,517 $ 29,766

Note 16 - Accumulated Other C_2

Note 16 - Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Unrealized Foreign loss on currency convertible translation notes gain (loss) receivables Total Balance May 31, 2022 $ 54,413 $ (75,177 ) $ (20,764 ) Other comprehensive loss (56,443 ) (2,525 ) (58,968 ) Balance August 31, 2022 $ (2,030 ) $ (77,702 ) $ (79,732 ) Other comprehensive loss (24,080 ) (17,643 ) (41,723 ) Balance November 30, 2022 $ (26,110 ) $ (95,345 ) $ (121,455 ) Other comprehensive (loss) reversal (16,838 ) 95,345 78,507 Balance February 28, 2023 $ (42,948 ) $ — $ (42,948 ) Balance May 31, 2023 $ (46,610 ) $ — $ (46,610 ) Other comprehensive loss 3,049 — 3,049 Balance August 31, 2023 $ (43,561 ) $ — $ (43,561 ) Other comprehensive loss 5,194 — 5,194 Balance November 30, 2023 $ (38,367 ) $ — $ (38,367 ) Other comprehensive loss (4,820 ) — (4,820 ) Balance February 29, 2024 $ (43,187 ) $ — $ (43,187 )

Note 17 - Non-controlling Int_2

Note 17 - Non-controlling Interests (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Condensed Balance Sheet [Table Text Block]	SH CC Pharma Aphria ColCanna February 29, Acquisition Nordic ApS Diamond S.A.S. 2024 Current assets $ — $ 31 $ 81,541 $ 191 $ 81,763 Non-current assets 32,000 — 129,067 3,719 164,786 Current liabilities — (14 ) (129,422 ) (6,786 ) (136,222 ) Non-current liabilities — — (48,218 ) (1,458 ) (49,676 ) Net assets $ 32,000 $ 17 $ 32,968 $ (4,334 ) $ 60,651 SH CC Pharma Aphria ColCanna May 31, Acquisition Nordic ApS Diamond S.A.S. 2023 Current assets $ — $ 114 $ 127,689 $ 224 $ 128,027 Non-current assets 74,681 — 135,085 3,307 213,073 Current liabilities — (1,166 ) (142,554 ) (6,697 ) (150,417 ) Non-current liabilities — — (53,197 ) (1,428 ) (54,625 ) Net assets $ 74,681 $ (1,052 ) $ 67,023 $ (4,594 ) $ 136,058
Condensed Income Statement [Table Text Block]	SH CC Pharma Aphria ColCanna February 29, Acquisition Nordic ApS Diamond S.A.S. 2024 Revenue $ — $ — $ 76,541 $ — $ 76,541 Total expenses 42,681 (1,078 ) 47,541 (594 ) 88,550 Net (loss) income (42,681 ) 1,078 29,000 594 (12,009 ) Other comprehensive (loss) income — (9 ) 646 (334 ) 303 Net comprehensive (loss) income $ (42,681 ) $ 1,069 $ 29,646 $ 260 $ (11,706 ) Non-controlling interest % 32 % 25 % 49 % 10 % NA Comprehensive (loss) income attributable to NCI (13,658 ) 267 14,527 26 1,162 Additional income attributable to NCI — — 5,336 — 5,336 Net comprehensive (loss) income attributable to NCI $ (13,658 ) $ 267 $ 19,863 $ 26 $ 6,498 SH CC Pharma Aphria ColCanna February 28, Acquisition Nordic ApS Diamond S.A.S. 2023 Revenue $ — $ 126 $ 98,960 $ — $ 99,086 Total expenses 107,297 659 54,285 91,026 253,267 Net (loss) income (107,297 ) (533 ) 44,675 (91,026 ) (154,181 ) Other comprehensive (loss) income 70,778 (13 ) (707 ) 373 70,431 Net comprehensive (loss) income $ (36,519 ) $ (546 ) $ 43,968 $ (90,653 ) $ (83,750 ) Non-controlling interest % 32 % 25 % 49 % 10 % NA Comprehensive (loss) income attributable to NCI (11,686 ) (137 ) 21,544 (9,065 ) 656 Additional income attributable to NCI — — 8,968 — 8,968 Net comprehensive (loss) income attributable to NCI $ (11,686 ) $ (137 ) $ 30,512 $ (9,065 ) $ 9,624

Note 19 - Commitments and Con_2

Note 19 - Commitments and Contingencies (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Contractual Obligation, Fiscal Year Maturity [Table Text Block]	Total 2024 2025 2026 2027 Thereafter Long-term debt repayment $ 178,977 $ 12,535 $ 44,319 $ 8,973 $ 10,335 $ 102,815 Convertible debentures payable 258,530 86,030 — — 172,500 — Material purchase obligations 49,159 21,587 27,572 — — — Construction commitments 822 822 — — — — Total $ 487,488 $ 120,974 $ 71,891 $ 8,973 $ 182,835 $ 102,815

Note 20 - Net Revenue (Tables)

Note 20 - Net Revenue (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Disaggregation of Revenue [Table Text Block]	For the three months ended For the nine months ended February 29, February 28, February 29, February 28, 2024 2023 2024 2023 Beverage alcohol revenue $ 58,247 $ 21,941 $ 133,237 $ 67,209 Beverage alcohol excise taxes (3,559 ) (1,301 ) (7,882 ) (4,520 ) Net beverage alcohol revenue 54,688 20,640 125,355 62,689 Cannabis revenue 85,236 61,118 276,676 203,503 Cannabis excise taxes (21,804 ) (13,569 ) (75,797 ) (47,486 ) Net cannabis revenue 63,432 47,549 200,879 156,017 Distribution revenue 56,794 65,385 193,174 186,158 Wellness revenue 13,426 12,015 39,652 38,072 Total $ 188,340 $ 145,589 $ 559,060 $ 442,936

Note 21 - Cost of Goods Sold (T

Note 21 - Cost of Goods Sold (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Schedule of Cost of Goods Sold [Table Text Block]	For the three months ended For the nine months ended February 29, February 28, February 29, February 28, 2024 2023 2024 2023 Beverage alcohol costs $ 35,836 $ 10,663 $ 77,615 $ 32,932 Cannabis costs 42,518 80,362 139,507 137,800 Distribution costs 51,231 57,964 172,846 165,443 Wellness costs 9,359 8,299 28,091 26,964 Total $ 138,944 $ 157,288 $ 418,059 $ 363,139

Note 22 - General and Adminis_2

Note 22 - General and Administrative Expenses (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Schedule of General and Administrative Expenses [Table Text Block]	For the three months ended For the nine months ended February 29, February 28, February 29, February 28, 2024 2023 2024 2023 Executive compensation $ 1,585 $ 2,754 $ 4,757 $ 9,359 Office and general 4,190 6,799 20,423 20,011 Salaries and wages 19,588 13,621 52,310 38,407 Stock-based compensation 8,059 9,630 24,517 29,766 Insurance 3,569 3,159 9,917 8,588 Professional fees 656 1,165 4,658 5,385 (Gain) loss on sale of capital assets 23 (15 ) 3 (2 ) Travel and accommodation 1,246 1,104 3,727 3,484 Rent 1,024 782 3,457 2,387 Total $ 39,940 $ 38,999 $ 123,769 $ 117,385

Note 24 - Non-operating Incom_2

Note 24 - Non-operating Income (Expense) (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	For the three months ended For the nine months ended February 29, February 28, February 29, February 28, 2024 2023 2024 2023 Change in fair value of convertible debenture payable $ (6,311 ) $ 207 $ (12,352 ) $ (20,375 ) Change in fair value of warrant liability 586 5,256 (1,365 ) 6,841 Foreign exchange loss (gain) (3,302 ) (1,955 ) 1,941 (26,621 ) Loss on long-term investments 33 (925 ) 383 (2,529 ) Other non-operating (losses) gains, net (8,245 ) (1,370 ) (9,427 ) (7,545 ) Total $ (17,239 ) $ 1,213 $ (20,820 ) $ (50,229 )

Note 25 - Fair Value Measurem_2

Note 25 - Fair Value Measurements (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	February 29, Level 1 Level 2 Level 3 2024 Financial assets Cash and cash equivalents $ 146,253 $ — $ — $ 146,253 Marketable securities 79,605 — — 79,605 Convertible notes receivable — — 32,000 32,000 Equity investments measured at fair value 1,104 1,454 5,500 8,058 Financial liabilities Warrant liability — — (3,182 ) (3,182 ) Contingent consideration — — (14,000 ) (14,000 ) APHA 24 Convertible debenture — — (83,351 ) (83,351 ) Total recurring fair value measurements $ 226,962 $ 1,454 $ (63,033 ) $ 165,383 May 31, Level 1 Level 2 Level 3 2023 Financial assets Cash and cash equivalents $ 206,632 $ — $ — $ 206,632 Marketable Securities 241,897 — — 241,897 Convertible notes receivable — — 103,401 103,401 Equity investments measured at fair value 1,056 1,088 5,651 7,795 Financial liabilities Warrant liability — — (1,817 ) (1,817 ) Contingent consideration — — (27,107 ) (27,107 ) APHA 24 Convertible debenture — — (120,568 ) (120,568 ) Total recurring fair value measurements $ 449,585 $ 1,088 $ (40,440 ) $ 410,233
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	APHA 24 Convertible Equity Warrant Contingent Convertible notes receivable Investments Liability Consideration Debt Balance, May 31, 2023 $ 103,401 $ 5,651 $ (1,817 ) $ (27,107 ) $ (120,568 ) Additions/(Repayments) — — — (4,181 ) 50,710 Redemption (28,720 ) — — 760 — Unrealized gain (loss) on fair value — (151 ) (1,365 ) 16,528 (13,493 ) Impairments (42,681 ) — — — — Balance, February 29, 2024 $ 32,000 $ 5,500 $ (3,182 ) $ (14,000 ) $ (83,351 )
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Significant Valuation unobservable Financial asset / financial liability technique input Inputs APHA Convertible debentures Black-Scholes Volatility, 50% expected life (in years) 0.3 Warrant liability Black-Scholes Volatility, 50% expected life (in years) 1.6 Contingent consideration Discounted cash flows Discount rate, 11 % achievement 95%

Note 26 - Segment Reporting (Ta

Note 26 - Segment Reporting (Tables)	9 Months Ended
	Feb. 29, 2024
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	For the three months ended For the nine months ended February 29, February 28, February 29, February 28, 2024 2023 2024 2023 Beverage alcohol Net beverage alcohol revenue $ 54,688 $ 20,640 $ 125,355 $ 62,689 Beverage alcohol costs 35,836 10,663 77,615 32,932 Beverage alcohol gross profit 18,852 9,977 47,740 29,757 Cannabis Net cannabis revenue 63,432 47,549 200,879 156,017 Cannabis costs 42,518 80,362 139,507 137,800 Cannabis gross profit (loss) 20,914 (32,813 ) 61,372 18,217 Distribution Distribution revenue 56,794 65,385 193,174 186,158 Distribution costs 51,231 57,964 172,846 165,443 Distribution gross profit 5,563 7,421 20,328 20,715 Wellness Wellness revenue 13,426 12,015 39,652 38,072 Wellness costs 9,359 8,299 28,091 26,964 Wellness gross profit $ 4,067 $ 3,716 $ 11,561 $ 11,108 For the three months ended For the nine months ended February 29, February 28, February 29, February 28, 2024 2023 2024 2023 Revenue from Canadian medical cannabis $ 6,363 $ 6,035 $ 18,793 $ 18,920 Revenue from Canadian adult-use cannabis 62,107 45,318 205,350 156,063 Revenue from wholesale cannabis 2,764 58 12,348 686 Revenue from international cannabis 14,002 9,707 40,185 27,834 Less excise taxes (21,804 ) (13,569 ) (75,797 ) (47,486 ) Total $ 63,432 $ 47,549 $ 200,879 $ 156,017
Revenue from External Customers by Geographic Areas [Table Text Block]	For the three months ended For the nine months ended February 29, February 28, February 29, February 28, 2024 2023 2024 2023 North America $ 117,524 $ 70,463 $ 325,664 $ 228,866 EMEA 67,143 71,111 222,139 199,867 Rest of World 3,673 4,015 11,257 14,203 Total $ 188,340 $ 145,589 $ 559,060 $ 442,936
Long-Lived Assets by Geographic Areas [Table Text Block]	February 29, May 31, 2024 2023 North America $ 473,779 $ 319,173 EMEA 101,271 107,131 Rest of World 3,733 3,363 Total $ 578,783 $ 429,667

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023	Jun. 22, 2023	May 31, 2023
Restricted Cash, Current	$ 0		$ 0			$ 0
Real Estate, Land, Held-for-Sale	$ 28,638,000		$ 28,638,000			$ 0
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities (in shares)	72,653,364	36,388,651	72,653,364	36,388,651
Restricted Stock Units (RSUs) [Member]
Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements (in shares)	20,652,315	16,431,876	20,652,315	16,431,876
Share-Based Payment Arrangement, Option [Member]
Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements (in shares)	5,744,302	4,660,046	5,744,302	4,660,046
Warrant [Member]
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants (in shares)	6,209,000	6,209,000	6,209,000	6,209,000
Kirkland Lake Property [Member]
Real Estate, Land, Held-for-Sale	$ 28,638		$ 28,638
Restricted Cash, Reserved for Letters of Credit and Acquisition-related Collateral [Member]
Restricted Cash, Current					$ 1,656

Note 2 - Inventory - Schedule o

Note 2 - Inventory - Schedule of Inventory (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Inventory	$ 244,139	$ 200,551
Beverage Alcohol Inventory [Member]
Inventory	47,606	27,837
Plants [Member]
Inventory	18,623	10,884
Dried Cannabis [Member]
Inventory	102,043	89,801
Cannabis Trim [Member]
Inventory	0	322
Cannabis Derivatives [Member]
Inventory	4,385	9,229
Cannabis Vapes [Member]
Inventory	5,250	1,173
Packaging and Other Inventory Items [Member]
Inventory	21,782	19,997
Tilray Pharma [Member]
Inventory	33,466	30,144
Wellness Inventory [Member]
Inventory	$ 10,984	$ 11,164

Note 3 - Capital Assets - Sched

Note 3 - Capital Assets - Schedule of Capital Assets (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Capital assets, gross	$ 763,848	$ 576,485
Less: accumulated amortization	(185,065)	(146,818)
Total	578,783	429,667
Land [Member]
Capital assets, gross	45,681	30,635
Manufacturing Facility [Member]
Capital assets, gross	388,234	344,627
Equipment [Member]
Capital assets, gross	253,422	185,422
Leasehold Improvements [Member]
Capital assets, gross	9,379	7,753
Right of Use Assets [Member]
Capital assets, gross	56,225	0
Construction in Progress [Member]
Capital assets, gross	$ 10,907	$ 8,048

Note 3 - Capital Assets - Asset

Note 3 - Capital Assets - Assets Held for Sale (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Assets, Held for sale	$ 28,638	$ 0
Land [Member]
Assets, Held for sale	1,380	0
Production Facility [Member]
Assets, Held for sale	20,821	0
Equipment [Member]
Assets, Held for sale	$ 6,437	$ 0

Note 4 - Leases - Lease Related

Note 4 - Leases - Lease Related Assets and Liabilities (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Finance lease, right-of-use assets	$ 56,225	$ 0
Operating lease, right-of-use assets	17,453	5,941
Total right-of-use asset	73,678	5,941
Total lease liabilities	78,652	10,359
Accrued Lease Obligation, Current [Member]
Current portion of finance lease liabilities	1,370	0
Current portion of operating lease liabilities	4,054	2,423
Accrued Lease Obligation, Non-current [Member]
Finance lease liabilities	55,674	0
Operating lease liabilities	$ 17,554	$ 7,936

Note 4 - Leases - Schedule of M

Note 4 - Leases - Schedule of Maturity (Details) $ in Thousands	Feb. 29, 2024 USD ($)
2024, operating	$ 1,635
2024, finance	1,261
2025, operating	5,715
2025, finance	5,043
2026, operating	5,361
2026, finance	5,043
2027, operating	4,768
2027, finance	5,043
Thereafter, operating	10,161
Thereafter, finance	85,336
Total minimum lease payments, operating	27,640
Total minimum lease payments	101,726
Imputed interest, operating	(6,032)
Imputed interest	(44,682)
Obligations recognized, operating	21,608
Obligations recognized	$ 57,044

Note 5 - Intangible Assets (Det

Note 5 - Intangible Assets (Details Textual) - USD ($)	Feb. 29, 2024	May 31, 2023
Licenses, Permits and Applications [Member]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$ 182,851	$ 181,093

Note 5 - Intangible Assets - Sc

Note 5 - Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Cost	$ 1,592,655	$ 1,576,717
Less: accumulated amortization	(246,706)	(187,088)
Less: impairments	(415,844)	(415,844)
Total	930,105	973,785
Customer Relationships and Distribution Channel [Member]
Cost	617,143	614,062
Licenses, Permits and Applications [Member]
Cost	368,649	366,793
Noncompete Agreements [Member]
Cost	12,422	12,394
Intellectual Property, Trademarks, Know How and Brands [Member]
Cost	$ 594,441	$ 583,468

Note 5 - Intangible Assets- Sch

Note 5 - Intangible Assets- Schedule of Estimated Amortization Expense (Details) $ in Thousands	Feb. 29, 2024 USD ($)
2024 (remaining three months)	$ 18,359
2025	73,439
2026	73,439
2027	73,439
2028	73,439
Thereafter	435,139
Total	$ 747,254

Note 6 - Goodwill - Carrying Am

Note 6 - Goodwill - Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Effect of foreign exchange	$ 8,664	$ 7,875
Impairments	(842,431)	(842,431)
Goodwill	2,009,632	2,008,843
Cannabis Segment [Member]
Goodwill, gross	2,640,669	2,640,669
Tilray Pharma [Member]
Goodwill, gross	4,458	4,458
Beverage Alcohol Business [Member]
Goodwill, gross	120,802	120,802
Wellness Business [Member]
Goodwill, gross	$ 77,470	$ 77,470

Note 7 - Business Acquisition_2

Note 7 - Business Acquisitions (Details Textual) $ / shares in Units, $ in Thousands, $ in Millions						3 Months Ended		9 Months Ended
	Sep. 29, 2023 USD ($)	Aug. 03, 2023 USD ($)	Aug. 03, 2023 CAD ($)	Jun. 22, 2023 USD ($) $ / shares shares	Nov. 07, 2022 USD ($) shares	Feb. 29, 2024 USD ($)	Feb. 28, 2023 USD ($)	Feb. 29, 2024 USD ($)	Feb. 28, 2023 USD ($)
Business Acquisition, Pro Forma Net Income (Loss)							$ 600		$ 1,800
Acquisition of Montauk Brewing Company, Inc. [Member]
Business Combination, Consideration Transferred					$ 35,123
Payments to Acquire Businesses, Gross					28,701
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable					6,422
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High					18,000
Business Combination, Contingent Consideration, Liability, Total					10,245
Business Acquisition, Pro Forma Revenue							3,100		12,100
Business Acquisition, Pro Forma Net Income (Loss)							(600)		1,100
Business Combination, Consideration Transferred, Liabilities Incurred					$ 10,245
Acquisition of Montauk Brewing Company, Inc. [Member] | Common Class 2 [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares					1,708,521
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable					$ 6,422
HEXO [Member]
Business Combination, Consideration Transferred				$ 93,882
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares				39,705,962
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable				$ 63,927
Business Acquisition, Pro Forma Revenue						$ 0	15,000	$ 7,000	55,000
Business Acquisition, Pro Forma Net Income (Loss)						0	25,000	1,800	85,000
Business Combination, Consideration Transferred, Settlement of Convertible Notes Receivable				28,720
Business Combination, Consideration Transferred, Fair Value of Stock Based Compensation				1,188
Business Combination, Consideration Transferred, Warrants Assumed				$ 47
Business Combination, Common Share Exchange Ratio				0.4352
Business Combination, Preferred Share Exchange Ratio				0.7805
Business Acquisition, Share Price (in dollars per share) | $ / shares				$ 1.61
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Litigation Settlement Accruals				$ 12,253
Truss Beverage Company [Member]
Payments to Acquire Businesses, Gross		$ 74	$ 0.1
Business Acquisition, Pro Forma Revenue						0		3,000
Business Acquisition, Pro Forma Net Income (Loss)						0	4,600	700	10,900
Business Acquisition, Percentage of Voting Interests Acquired		57.50%	57.50%
Truss Beverage Company [Member] | Contingent Consideration [Member]
Business Combination, Consideration Transferred, Liabilities Incurred		$ 4,181
Business Combination, Contingent Consideration, Liability, Settlement Payment						760
Business Combination, Contingent Consideration, Gain/(Loss) from Change in Fair Value						3,683
Foreign Exchange Impact						262		262
Craft Beverage Business Acquisition [Member]
Payments to Acquire Businesses, Gross	$ 83,658
Business Acquisition, Pro Forma Revenue						0	33,000	55,000	118,000
Business Acquisition, Pro Forma Net Income (Loss)						$ 0	$ 3,500	$ 5,000	$ 4,400
Number of Brands Acquired	8
Working Capital Adjustment	$ 1,342
Craft Beverage Business Acquisition [Member] | Delayed Draw Term Loan Agreement [Member]
Long-Term Debt	$ 20,000

Note 7 - Business Acquisition_3

Note 7 - Business Acquisitions - Assets Acquired and Liabilities Assumed (Details) $ in Thousands, $ in Millions	Sep. 29, 2023 USD ($)	Aug. 03, 2023 USD ($)	Aug. 03, 2023 CAD ($)	Jun. 22, 2023 USD ($)	Nov. 07, 2022 USD ($)	Feb. 29, 2024 USD ($)	May 31, 2023 USD ($)
Goodwill						$ 2,009,632	$ 2,008,843
Finance lease, right-of-use assets	$ 45,496
Acquisition of Montauk Brewing Company, Inc. [Member]
Cash					$ 28,701
Shares					6,422
Contingent consideration					10,245
Cash and cash equivalents					1,983
Accounts receivable					1,116
Prepaids and other current assets					467
Inventory					1,570
Capital assets					420
Goodwill					17,803
Total assets					55,549
Accounts payable and accrued liabilities					1,580
Deferred tax liability					4,851
Other liabilities					3,750
Total liabilities					10,181
Total net assets acquired					45,368
Acquisition of Montauk Brewing Company, Inc. [Member] | Customer Relationships [Member]
Finite-lived intangible assets					18,540
Acquisition of Montauk Brewing Company, Inc. [Member] | Intellectual Property, Trademarks and Brands [Member]
Finite-lived intangible assets					$ 13,650
HEXO [Member]
Shares				$ 63,927
Cash and cash equivalents				14,634
Accounts receivable				7,855
Prepaids and other current assets				2,709
Inventory				25,947
Capital assets				70,634
Finite-lived intangible assets				2,680
Accounts payable and accrued liabilities				44,517
Total liabilities				44,517
Total net assets acquired				93,882
Settlement of convertible notes receivable				28,720
Warrants assumed				47
Estimated fair value of HEXO stock-based compensation				1,188
Restricted cash				1,656
Asset held for sale				755
Prepaid expenses				8,384
Interest in equity investee				3,145
Total assets				$ 138,399
Truss Beverage Company [Member]
Cash		$ 74	$ 0.1
Cash and cash equivalents		6,739
Accounts receivable		1,038
Prepaids and other current assets		78
Inventory		2,573
Finite-lived intangible assets		296
Accounts payable and accrued liabilities		5,408
Total liabilities		6,284
Total net assets acquired		7,400
Asset held for sale		2,960
Total assets		13,684
Investment in equity investees		3,145
Other liabilities		876
Truss Beverage Company [Member] | Contingent Consideration [Member]
Contingent consideration		$ 4,181
Craft Beverage Business Acquisition [Member]
Cash	83,658
Cash and cash equivalents	77
Prepaids and other current assets	573
Inventory	22,493
Capital assets	62,614
Accounts payable and accrued liabilities	2,206
Total liabilities	55,380
Total net assets acquired	83,658
Total assets	139,038
Operating lease, right-of-use assets	7,677
Other assets	108
Current portion of finance lease liabilities	1,031
Current portion of operating lease liabilities	1,408
Finance lease liabilities	44,465
Operating lease liabilities	$ 6,270

Note 7 - Business Acquisition_4

Note 7 - Business Acquisitions - Assets Acquired and Liabilities Assumed (Details) (Parentheticals)	Jun. 22, 2023	Nov. 07, 2022
Acquisition of Montauk Brewing Company, Inc. [Member] | Customer Relationships [Member]
Estimated useful life (Year)		15 years
Acquisition of Montauk Brewing Company, Inc. [Member] | Intellectual Property, Trademarks and Brands [Member]
Estimated useful life (Year)		15 years
HEXO [Member]
Estimated useful life (Year)	15 years

Note 8 - Convertible Notes Re_3

Note 8 - Convertible Notes Receivable (Details Textual) $ in Thousands		3 Months Ended		9 Months Ended
	Aug. 31, 2021 USD ($) shares	Feb. 29, 2024 USD ($)	Feb. 28, 2023 USD ($)	Feb. 29, 2024 USD ($)	Feb. 28, 2023 USD ($)
Other-than-temporary Fair Value Loss, Convertible Notes Receivable		$ 42,681	$ 181,376	$ 42,681	$ 181,376
MM Notes [Member]
Financing Receivable, before Allowance for Credit Loss, Total	$ 165,799
Notes Receivable, SOFR Floor	2.50%
Other-than-temporary Fair Value Loss, Convertible Notes Receivable		42,681
MM Notes [Member] | Convertible Debt [Member]
Interest Income, Purchased Receivables		$ 0		$ 0
MM Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]
Notes Receivable, Measurement Input	0.035
MM Notes [Member] | Measurement Input, Price Volatility [Member]
Notes Receivable, Measurement Input	0.70
MM Notes [Member] | Measurement Input, Forfeiture Rate [Member]
Notes Receivable, Measurement Input	0
MM Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Notes Receivable, Measurement Input	0
MM Notes [Member] | Measurement Input, Probability of Legalization [Member] | Minimum [Member]
Notes Receivable, Measurement Input	0
MM Notes [Member] | Measurement Input, Probability of Legalization [Member] | Maximum [Member]
Notes Receivable, Measurement Input	0.60
MM Notes [Member] | Secured Overnight Financing Rate (SOFR) [Member]
Notes Receivable, Interest Rate, Basis Spread on Variable Rate	6%
Superhero Acquisition LP [Member]
Noncontrolling Interest, Ownership Percentage by Parent	68%	68%		68%
The MM Notes and MM Warrants [Member]
Stock Issued During Period, Shares, Acquisitions (in shares) | shares	9,817,061
Stock Issued During Period, Value, Acquisitions	$ 117,804

Note 8 - Convertible Notes Re_4

Note 8 - Convertible Notes Receivable - Schedule of Convertible Notes Receivable (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Total convertible notes receivable	$ 32,000	$ 103,401
Deduct - current portion	0	0
Total convertible notes receivable, non current portion	32,000	103,401
HEXO Convertible Notes Receivable [Member]
Total convertible notes receivable	0	28,720
MedMen Convertible Note [Member]
Total convertible notes receivable	$ 32,000	$ 74,681

Note 9 - Long-term Investments

Note 9 - Long-term Investments - Schedule of Long-term Investments (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Equity investments measured at fair value	$ 2,558	$ 2,144
Equity investments under measurement alternative	5,500	5,651
Total	$ 8,058	$ 7,795

Note 10 - Bank Indebtedness (De

Note 10 - Bank Indebtedness (Details Textual) € in Thousands, $ in Thousands, $ in Thousands	3 Months Ended
	Feb. 29, 2024 USD ($)	Feb. 29, 2024 CAD ($)	Feb. 29, 2024 EUR (€)
Four Twenty Corporation [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 30,000
Long-Term Line of Credit, Total	$ 7,000
Line of Credit [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	75%
Line of Credit [Member] | Aphria Inc [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 1,000
Long-Term Line of Credit, Total		$ 0
Line of Credit [Member] | CC Pharma GmbH [Member]
Line of Credit Facility, Maximum Borrowing Capacity | €			€ 7,500
Long-Term Line of Credit, Total	$ 8,029		€ 7,434
Number of Debt Instruments	2	2	2
Line of Credit [Member] | CC Pharma GmbH [Member] | Euro Short-Term Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	2.50%
Line of Credit [Member] | CC Pharma GmbH [Member] | Euro Interbank Offered Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	4%
Operating Line of Credit One [Member] | CC Pharma GmbH [Member]
Line of Credit Facility, Maximum Borrowing Capacity | €			€ 7,000
Operating Line of Credit Two [Member] | CC Pharma GmbH [Member]
Line of Credit Facility, Maximum Borrowing Capacity | €			€ 500

Note 11 - Accounts Payable an_3

Note 11 - Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Trade payables	$ 90,163	$ 70,819
Accrued liabilities	70,744	48,394
Litigation accrual	25,153	25,000
Accrued payroll and employment related taxes	14,993	18,772
Income taxes payable	1,438	14,934
Accrued interest	3,202	8,102
Sales taxes payable	4,070	4,661
Total	$ 209,763	$ 190,682

Note 12 - Long-term Debt (Detai

Note 12 - Long-term Debt (Details Textual) - Secured Debt [Member] $ in Millions		3 Months Ended
	Aug. 31, 2023 USD ($)	Aug. 31, 2023 USD ($)
Term Loan Due In March Two Thousand Twenty Four [Member] | Four Twenty Corporation [Member]
Repayments of Long-Term Debt		$ 100
Term Loan Due In June Two Thousand Twenty Eight [Member]
Long-Term Debt, Gross	$ 70	70
Debt Instrument, Maturity Date	Jun. 30, 2028
Term Loan Due In June Two Thousand Twenty Eight [Member] | Delayed Draw Term Loan [Member]
Long-Term Debt, Gross	$ 20	$ 20

Note 12 - Long-term Debt - Net

Note 12 - Long-term Debt - Net Carrying Amount of Long-term Debt Instruments (Details) € in Thousands, $ in Thousands	Feb. 29, 2024 USD ($)	Feb. 29, 2024 EUR (€)	May 31, 2023 USD ($)	May 31, 2023 EUR (€)
Credit Facility Due in November 2025 [Member]
Carrying amount of long-term debt	$ 41,440		$ 45,260
Term Loan Due in July 2033 [Member]
Carrying amount of long-term debt	10,541		10,959
Term Loan Due in July 2033 Two [Member]
Carrying amount of long-term debt	12,765		13,092
Term Loan Due in August 2026 [Member]
Carrying amount of long-term debt	288		346
Mortgage Payable Due in August 2026 [Member]
Carrying amount of long-term debt	2,122		2,104
Term Loan Due in December 2023, One [Member]
Carrying amount of long-term debt	0		803
Term Loan Due in December 2023, Two [Member]
Carrying amount of long-term debt	0		755
Term Loan Due in April 2025 [Member]
Carrying amount of long-term debt	520		819
Term Loan Due in August 2028 [Member]
Carrying amount of long-term debt | €		€ 3,326		€ 1,706
Mortgage Payable Due in October 2030 [Member]
Carrying amount of long-term debt	20,225		20,863
Term Loan Due in June 2028 [Member]
Carrying amount of long-term debt	87,750		65,000
Long-term Debt, Excluding Convertible Debentures [Member]
Carrying amount of long-term debt	178,977		161,707
Unamortized financing fees	(978)		(738)
Net carrying amount	177,999		160,969
Less principal portion included in current liabilities	(12,351)		(24,080)
Total noncurrent portion of long-term debt	$ 165,648		$ 136,889

Note 12 - Long-term Debt - Ne_2

Note 12 - Long-term Debt - Net Carrying Amount of Long-term Debt Instruments (Details) (Parentheticals) € in Thousands, $ in Thousands, $ in Thousands	9 Months Ended			12 Months Ended
	Feb. 29, 2024 USD ($)	Feb. 29, 2024 CAD ($)	Feb. 29, 2024 EUR (€)	May 31, 2023 USD ($)	May 31, 2023 CAD ($)	May 31, 2023 EUR (€)	Feb. 29, 2024 CAD ($)	Feb. 29, 2024 EUR (€)	May 31, 2023 CAD ($)	May 31, 2023 EUR (€)
Credit Facility Due in November 2025 [Member]
Face amount							$ 66,000		$ 66,000
Term (Year)	3 years	3 years	3 years	3 years	3 years	3 years
Amortization period (Year)	10 years	10 years	10 years	10 years	10 years	10 years
Maturity	Nov. 30, 2025	Nov. 30, 2025	Nov. 30, 2025	Nov. 30, 2025	Nov. 30, 2025	Nov. 30, 2025
Term Loan Due in July 2033 [Member]
Face amount							25,000		25,000
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Amortization period (Year)	15 years	15 years	15 years	15 years	15 years	15 years
Maturity	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033
Periodic payment		$ 181			$ 181
Term Loan Due in July 2033 [Member] | Prime Rate [Member]
Variable rate	1%	1%	1%	1%	1%	1%
Term Loan Due in July 2033 Two [Member]
Face amount							25,000		25,000
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Amortization period (Year)	15 years	15 years	15 years	15 years	15 years	15 years
Maturity	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033
Variable rate	1%	1%	1%	1%	1%	1%
Periodic payment		$ 196			$ 196
Term Loan Due in August 2026 [Member]
Face amount							1,250		1,250
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Amortization period (Year)	10 years	10 years	10 years	10 years	10 years	10 years
Maturity	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026
Periodic payment		$ 12			$ 12
Term Loan Due in August 2026 [Member] | Prime Rate [Member]
Variable rate	1.50%	1.50%	1.50%	1.50%	1.50%	1.50%
Mortgage Payable Due in August 2026 [Member]
Face amount							$ 3,750		$ 3,750
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Amortization period (Year)	20 years	20 years	20 years	20 years	20 years	20 years
Maturity	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026
Periodic payment		$ 23			$ 23
Mortgage Payable Due in August 2026 [Member] | Prime Rate [Member]
Variable rate	1.50%	1.50%	1.50%	1.50%	1.50%	1.50%
Term Loan Due in December 2023, One [Member]
Face amount | €								€ 5,000		€ 5,000
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Maturity	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023
Periodic payment | €			€ 250			€ 250
Term Loan Due in December 2023, One [Member] | Euro Interbank Offered Rate [Member]
Variable rate	2.15%	2.15%	2.15%	2.15%	2.15%	2.15%
Term Loan Due in December 2023, Two [Member]
Face amount | €								€ 1,200		€ 1,200
Term (Year)	1 year	1 year	1 year	1 year	1 year	1 year
Maturity	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023
Periodic payment | €			€ 100			€ 100
Rate	4.26%			4.26%			4.26%	4.26%	4.26%	4.26%
Term Loan Due in April 2025 [Member]
Face amount | €								€ 1,500		€ 1,500
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Maturity	Apr. 30, 2025	Apr. 30, 2025	Apr. 30, 2025	Apr. 30, 2025	Apr. 30, 2025	Apr. 30, 2025
Periodic payment | €			€ 94			€ 94
Rate	2%			2%			2%	2%	2%	2%
Term Loan Due in August 2028 [Member]
Face amount	$ 3,500			$ 3,500
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Maturity	Aug. 31, 2028	Aug. 31, 2028	Aug. 31, 2028	Aug. 31, 2028	Aug. 31, 2028	Aug. 31, 2028
Periodic payment | €			€ 52			€ 52
Rate	4.59%			4.59%			4.59%	4.59%	4.59%	4.59%
Mortgage Payable Due in October 2030 [Member]
Face amount	$ 22,635			$ 22,635
Term (Year)	10 years	10 years	10 years	10 years	10 years	10 years
Maturity	Oct. 31, 2030	Oct. 31, 2030	Oct. 31, 2030	Oct. 31, 2030	Oct. 31, 2030	Oct. 31, 2030
Periodic payment	$ 57			$ 57
Mortgage Payable Due in October 2030 [Member] | Euro Interbank Offered Rate [Member]
Variable rate	1.50%	1.50%	1.50%	1.50%	1.50%	1.50%
Term Loan Due in June 2028 [Member]
Face amount	$ 90,000			$ 90,000
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Maturity	Jun. 30, 2028	Jun. 30, 2028	Jun. 30, 2028	Jun. 30, 2028	Jun. 30, 2028	Jun. 30, 2028
Term Loan Due in June 2028 [Member] | Minimum [Member]
Periodic payment	$ 875			$ 875
Term Loan Due in June 2028 [Member] | Maximum [Member]
Periodic payment	$ 1,750			$ 1,750

Note 13 - Convertible Debentu_3

Note 13 - Convertible Debentures Payable (Details Textual)				1 Months Ended	3 Months Ended				9 Months Ended		12 Months Ended
	Oct. 02, 2023 USD ($)	Sep. 12, 2023 USD ($) shares	May 30, 2023 USD ($) $ / shares shares	Apr. 30, 2019	Feb. 29, 2024 USD ($) shares	Nov. 30, 2023 USD ($)	Feb. 28, 2023 USD ($)	Aug. 31, 2022 USD ($)	Feb. 29, 2024 USD ($) shares	Feb. 28, 2023 USD ($)	May 31, 2023 USD ($)	Jul. 12, 2022 USD ($)	Apr. 01, 2019 USD ($) $ / shares
Accretion Expense									$ 11,463,000	$ 7,941,000
Convertible Debt, Current					$ 83,351,000				83,351,000		$ 174,378,000
Repayments of Convertible Debt									107,330,000	0
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature						$ 1,672,000
Other Nonoperating Gains (Losses)					(8,245,000)		$ (1,370,000)		(9,427,000)	(7,545,000)
TLRY 27 [Member]
Debt Instrument, Face Amount			$ 172,500,000		$ 172,500,000				$ 172,500,000		$ 150,000,000
Debt Instrument, Interest Rate, Stated Percentage			5.20%		5.20%				5.20%		5.20%
Debt Instrument, Convertible, Conversion Ratio			376.6478
Debt Instrument, Convertible, Multiples of Principal Amount			$ 1,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares			$ 2.66
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger			130%
Own-share Lending Arrangement, Shares, Issued (in shares) | shares			38,500,000
Interest Expense, Debt					$ 2,243,000				$ 6,728,000
Accretion Expense					$ 2,896,000				$ 8,520,000
HT Investments MA LLC Note [Member]
Debt Instrument, Face Amount											$ 50,000,000	$ 50,000,000
Debt Instrument, Interest Rate, Stated Percentage					4%				4%		4%	4%
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature								$ 9,055,000
APHA 24 [Member]
Debt Instrument, Face Amount					$ 350,000,000				$ 350,000,000		$ 350,000,000		$ 350,000,000
Debt Instrument, Interest Rate, Stated Percentage					5.25%				5.25%		5.25%		5.25%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares													$ 11.2
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger				130%
Interest Expense, Debt					$ 1,483,000		3,319,000		$ 5,072,000	10,105,000
Debt Instrument, Convertible, Threshold Trading Days				20
Debt Instrument, Convertible, Threshold Consecutive Trading Days				30
Debt Instrument, Redemption Price, Including Interest, Percentage				100%
Debt Instrument, Repurchase Amount					$ 50,710,000				$ 50,710,000
Stock Issued During Period, Shares, For The Repayment of Convertible Debt (in shares) | shares					27,228,252				27,228,252
Debt Instrument, Increase (Decrease), Net									$ (13,493,000)
Debt Instrument, Fair Value Adjustment									12,352,000
Foreign Exchange Impact					$ 1,141,000				1,141,000
Convertible Debt, Current					86,030,000				86,030,000		$ 136,740,000
Repayments of Convertible Debt					263,970,000						213,260,000
TLRY 23 [Member]
Debt Instrument, Face Amount					$ 0				$ 0		$ 277,856,000
Debt Instrument, Interest Rate, Stated Percentage					5%				5%		5%
Interest Expense, Debt					$ 0		$ 1,748,000		$ 2,122,000	$ 6,077,000
Debt Instrument, Repurchase Amount		$ 20,000,000
Stock Issued During Period, Shares, For The Repayment of Convertible Debt (in shares) | shares		7,000,000							7,000,000
Repayments of Convertible Debt	$ 107,330,000	$ 610,000			$ 0						$ 150,526,000
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature		1,672,000
Other Nonoperating Gains (Losses)		$ (1,062,000)

Note 13 - Convertible Debentu_4

Note 13 - Convertible Debentures Payable - Net Carrying Amount of Convertible Debentures (Details) - USD ($) $ in Thousands			3 Months Ended	9 Months Ended		12 Months Ended
	Oct. 02, 2023	Sep. 12, 2023	Feb. 29, 2024	Feb. 29, 2024	Feb. 28, 2023	May 31, 2023	May 30, 2023	Jul. 12, 2022	Apr. 01, 2019
Deduct - current portion			$ 83,351	$ 83,351		$ 174,378
Total convertible debentures payable, non current portion			126,587	126,587		221,044
Debt settlement				(107,330)	$ 0
HT Investments MA LLC Note [Member]
Carrying amount of long-term debt			0	0		47,834
Debt instrument			0	0		47,834
Carrying amount of long-term debt			$ 0	$ 0		47,834
Contractual debenture						50,000		$ 50,000
Unamortized discount						(2,166)
Convertible debentures						$ 47,834
Rate			4%	4%		4%		4%
TLRY 27 [Member]
Carrying amount of long-term debt			$ 126,587	$ 126,587		$ 100,476
Debt instrument			126,587	126,587		100,476
Carrying amount of long-term debt			126,587	126,587		100,476
Contractual debenture			172,500	172,500		150,000	$ 172,500
Unamortized discount			(45,913)	(45,913)		(49,524)
Convertible debentures			$ 126,587	$ 126,587		$ 100,476
Rate			5.20%	5.20%		5.20%	5.20%
APHA 24 [Member]
Carrying amount of long-term debt			$ 83,351	$ 83,351		$ 120,568
Debt instrument			83,351	83,351		120,568
Carrying amount of long-term debt			83,351	83,351		120,568
Deduct - current portion			86,030	86,030		136,740
Contractual debenture			350,000	350,000		350,000			$ 350,000
Convertible debentures			$ 83,351	$ 83,351		$ 120,568
Rate			5.25%	5.25%		5.25%			5.25%
Debt settlement			$ (263,970)			$ (213,260)
Fair value adjustment			(2,679)			(16,172)
TLRY 23 [Member]
Carrying amount of long-term debt			0	$ 0		126,544
Debt instrument			0	0		126,544
Carrying amount of long-term debt			0	0		126,544
Contractual debenture			0	0		277,856
Unamortized discount			0	0		(786)
Convertible debentures			$ 0	$ 0		$ 126,544
Rate			5%	5%		5%
Debt settlement	$ (107,330)	$ (610)	$ 0			$ (150,526)
Convertible Debentures [Member]
Carrying amount of long-term debt			209,938	$ 209,938		395,422
Debt instrument			209,938	209,938		395,422
Carrying amount of long-term debt			$ 209,938	$ 209,938		$ 395,422

Note 13 - Convertible Debentu_5

Note 13 - Convertible Debentures Payable - Net Carrying Amount of Convertible Debentures (Details) (Parentheticals)	Feb. 29, 2024	May 31, 2023	May 30, 2023	Jul. 12, 2022	Apr. 01, 2019
TLRY 27 [Member]
Rate	5.20%	5.20%	5.20%
Interest rate	5.20%	5.20%	5.20%
HT Investments MA LLC Note [Member]
Rate	4%	4%		4%
Interest rate	4%	4%		4%
APHA 24 [Member]
Rate	5.25%	5.25%			5.25%
Interest rate	5.25%	5.25%			5.25%
TLRY 23 [Member]
Rate	5%	5%
Interest rate	5%	5%

Note 14 - Warrant Liability (De

Note 14 - Warrant Liability (Details Textual) - $ / shares	Feb. 29, 2024	May 31, 2023	May 01, 2023
Class of Warrant or Right, Outstanding (in shares)	6,209,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 5.95		$ 5.95
Percentage of Daily Cash Penalty	1%
Fair Value, Inputs, Level 3 [Member]
Estimated Fair Value of Warrant Liability Per Warrant (in dollars per share)	$ 0.512
Fair Value, Inputs, Level 3 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.039
Fair Value, Inputs, Level 3 [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.50
Fair Value, Inputs, Level 3 [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	1.55
Fair Value, Inputs, Level 3 [Member] | Measurement Input, Conversion Price [Member]
Warrants and Rights Outstanding, Measurement Input	1.61
Fair Value, Inputs, Level 3 [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input	1.73
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.61
Warrants to Purchase Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1	1

Note 15 - Stockholders' Equit_2

Note 15 - Stockholders' Equity (Details Textual) - USD ($) $ in Thousands				3 Months Ended					9 Months Ended		12 Months Ended
	Oct. 02, 2023	Sep. 12, 2023	Jul. 12, 2022	Feb. 29, 2024	Aug. 31, 2023	Feb. 28, 2023	Nov. 30, 2022	Aug. 31, 2022	Feb. 29, 2024	Feb. 28, 2023	May 31, 2023
Common Stock, Shares Authorized (in shares)				1,198,000,000					1,198,000,000		1,198,000,000
Preferred Stock, Shares Authorized (in shares)				10,000,000					10,000,000		10,000,000
Common Stock, Shares, Issued (in shares)				774,028,053					774,028,053		656,655,455
Preferred Stock, Shares Issued (in shares)				0					0		0
Stock Issued During Period, Value, Settlement of Financing Liability				$ 2,383	$ 8,146	$ 7,678	$ 6,474	$ 5,064
Repayments of Convertible Debt									$ 107,330	$ 0
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture (in shares)									4,186,523
Share-Based Payment Arrangement, Expense				$ 8,059		$ 9,630			$ 24,517	$ 29,766
Common Stock, Shares, Outstanding (in shares)				774,028,053					774,028,053		656,655,455
Preferred Stock, Shares Outstanding (in shares)				0					0		0
Time-based Restricted Stock Units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									11,559,549	6,004,995
Performance-based Restricted Stock Units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									7,566,146	2,634,744
HT Investments MA LLC Note [Member]
Stock Issued During Period, Shares, For Derivative Settlement (Downside Protection) (in shares)									17,148,541
HT Investments MA LLC Note [Member] | Derivative Settlement [Member]
Stock Issued During Period, Shares, For Derivative Settlement (Downside Protection) (in shares)									1,032,616
HTI Convertible Note Payable [Member]
Repayments of Convertible Debt			$ 50,000
Tilray Brands Inc MediPharm / HEXO Litigation Settlement [Member]
Stock Issued During Period, Shares, Legal Settlement (in shares)									1,573,152
TLRY 23 [Member]
Repayments of Convertible Debt	$ 107,330	$ 610		$ 0							$ 150,526
Stock Issued During Period, Shares, For The Repayment of Convertible Debt (in shares)		7,000,000							7,000,000
Convertible Debt Instrument, Repurchase Amount				20,000					$ 20,000
APHA 24 [Member]
Repayments of Convertible Debt				$ 263,970							$ 213,260
Stock Issued During Period, Shares, For The Repayment of Convertible Debt (in shares)				27,228,252					27,228,252
Convertible Debt Instrument, Repurchase Amount				$ 50,710					$ 50,710
Aphria Diamond [Member]
Stock Issued During Period, Shares, Settlement of Dividend Payable (in shares)									18,632,126
HEXO [Member]
Stock Issued During Period, Shares, Purchase of Assets (in shares)									39,705,962
Stock Issued During Period, Shares, Settlement of Financing Liability (in shares)									865,426
Stock Issued During Period, Value, Settlement of Financing Liability									$ 1,500

Note 15 - Stockholders' Equit_3

Note 15 - Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Stock-based compensation expense	$ 8,059	$ 9,630	$ 24,517	$ 29,766
Share-Based Payment Arrangement, Option [Member]
Stock-based compensation expense		20		644
Restricted Stock Units (RSUs) [Member]
Stock-based compensation expense	$ 8,059	$ 9,610	$ 24,517	$ 29,122

Note 16 - Accumulated Other C_3

Note 16 - Accumulated Other Comprehensive Income (Loss) - Components of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Feb. 29, 2024	Nov. 30, 2023	Aug. 31, 2023	Feb. 28, 2023	Nov. 30, 2022	Aug. 31, 2022	Feb. 29, 2024	Feb. 28, 2023
Balance	$ 3,393,353	$ 3,401,556	$ 3,329,943	$ 4,483,146	$ 4,563,182	$ 4,441,366	$ 3,329,943	$ 4,441,366
Other comprehensive loss	(4,696)			101,735			3,716	(3,322)
Balance	3,343,041	3,393,353	3,401,556	3,406,771	4,483,146	4,563,182	3,343,041	3,406,771
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	(38,367)	(43,561)	(46,610)	(26,110)	(2,030)	54,413	(46,610)	54,413
Other comprehensive loss	(4,820)	5,194	3,049	(16,838)	(24,080)	(56,443)
Balance	(43,187)	(38,367)	(43,561)	(42,948)	(26,110)	(2,030)	(43,187)	(42,948)
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]
Balance	0	0	0	(95,345)	(77,702)	(75,177)	0	(75,177)
Other comprehensive loss	0	0	0	95,345	(17,643)	(2,525)
Balance	0	0	0	0	(95,345)	(77,702)	0	0
Unrealized Loss on Available for Sale Debt Securities [Member]
Balance	(38,367)	(43,561)	(46,610)	(121,455)	(79,732)	(20,764)	(46,610)	(20,764)
Other comprehensive loss	(4,820)	5,194	3,049	78,507	(41,723)	(58,968)
Balance	$ (43,187)	$ (38,367)	$ (43,561)	$ (42,948)	$ (121,455)	$ (79,732)	$ (43,187)	$ (42,948)

Note 17 - Non-controlling Int_3

Note 17 - Non-controlling Interests (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023	Aug. 31, 2021
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest	$ (12,158)	$ (1,526)	$ 6,498	$ 9,624
Subsidiaries [Member]
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest			$ 1,162	656
Subsidiaries [Member] | Wholesale Cannabis Supply Agreement [Member]
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest	$ (15,000)
Superhero Acquisition LP [Member]
Noncontrolling Interest, Ownership Percentage by Parent	68%		68%		68%
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest			$ (13,658)	(11,686)
CC Pharma Nordic ApS [Member]
Noncontrolling Interest, Ownership Percentage by Parent	75%		75%
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest			$ 267	(137)
Aphria Diamond [Member]
Noncontrolling Interest, Ownership Percentage by Parent	51%		51%
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest			$ 14,527	21,544
ColCanna S.A.S. [Member]
Noncontrolling Interest, Ownership Percentage by Parent	90%		90%
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest			$ 26	$ (9,065)

Note 17 - Non-controlling Int_4

Note 17 - Non-controlling Interests - Summary of Balance Sheet Information (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Current assets	$ 631,211	$ 773,029
Current liabilities	(329,100)	(432,979)
Superhero Acquisition LP [Member]
Current assets	0	0
Non-current assets	32,000	74,681
Current liabilities	0	0
Non-current liabilities	0	0
Net assets	32,000	74,681
CC Pharma Nordic ApS [Member]
Current assets	31	114
Non-current assets	0	0
Current liabilities	(14)	(1,166)
Non-current liabilities	0	0
Net assets	17	(1,052)
Aphria Diamond [Member]
Current assets	81,541	127,689
Non-current assets	129,067	135,085
Current liabilities	(129,422)	(142,554)
Non-current liabilities	(48,218)	(53,197)
Net assets	32,968	67,023
ColCanna S.A.S. [Member]
Current assets	191	224
Non-current assets	3,719	3,307
Current liabilities	(6,786)	(6,697)
Non-current liabilities	(1,458)	(1,428)
Net assets	(4,334)	(4,594)
Subsidiaries [Member]
Current assets	81,763	128,027
Non-current assets	164,786	213,073
Current liabilities	(136,222)	(150,417)
Non-current liabilities	(49,676)	(54,625)
Net assets	$ 60,651	$ 136,058

Note 17 - Non-controlling Int_5

Note 17 - Non-controlling Interests - Summary of Income Statement Information (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Feb. 29, 2024	Nov. 30, 2023	Aug. 31, 2023	Feb. 28, 2023	Nov. 30, 2022	Aug. 31, 2022	Feb. 29, 2024	Feb. 28, 2023
Net (loss) income	$ (104,983)			$ (1,195,752)			$ (207,029)	$ (1,323,181)
Other comprehensive (loss) income	(4,696)			101,735			3,716	(3,322)
Net comprehensive (loss) income	(109,679)	$ (40,980)	$ (52,654)	(1,094,017)	$ (103,875)	$ (128,611)	(203,313)	(1,326,503)
Comprehensive (loss) income attributable to NCI	$ (12,158)			$ (1,526)			6,498	9,624
Subsidiaries [Member]
Revenue							76,541	99,086
Total expenses							88,550	253,267
Net (loss) income							(12,009)	(154,181)
Other comprehensive (loss) income							303	70,431
Net comprehensive (loss) income							(11,706)	(83,750)
Comprehensive (loss) income attributable to NCI							1,162	656
Additional income attributable to NCI							5,336	8,968
Net comprehensive (loss) income attributable to NCI							6,498	9,624
Superhero Acquisition LP [Member]
Revenue							0	0
Total expenses							42,681	107,297
Net (loss) income							(42,681)	(107,297)
Other comprehensive (loss) income							0	70,778
Net comprehensive (loss) income							$ (42,681)	$ (36,519)
Non-controlling interest %	32%			32%			32%	32%
Comprehensive (loss) income attributable to NCI							$ (13,658)	$ (11,686)
Additional income attributable to NCI							0	0
Net comprehensive (loss) income attributable to NCI							(13,658)	(11,686)
CC Pharma Nordic ApS [Member]
Revenue							0	126
Total expenses							(1,078)	659
Net (loss) income							1,078	(533)
Other comprehensive (loss) income							(9)	(13)
Net comprehensive (loss) income							$ 1,069	$ (546)
Non-controlling interest %	25%			25%			25%	25%
Comprehensive (loss) income attributable to NCI							$ 267	$ (137)
Additional income attributable to NCI							0	0
Net comprehensive (loss) income attributable to NCI							267	(137)
Aphria Diamond [Member]
Revenue							76,541	98,960
Total expenses							47,541	54,285
Net (loss) income							29,000	44,675
Other comprehensive (loss) income							646	(707)
Net comprehensive (loss) income							$ 29,646	$ 43,968
Non-controlling interest %	49%			49%			49%	49%
Comprehensive (loss) income attributable to NCI							$ 14,527	$ 21,544
Additional income attributable to NCI							5,336	8,968
Net comprehensive (loss) income attributable to NCI							19,863	30,512
ColCanna S.A.S. [Member]
Revenue							0	0
Total expenses							(594)	91,026
Net (loss) income							594	(91,026)
Other comprehensive (loss) income							(334)	373
Net comprehensive (loss) income							$ 260	$ (90,653)
Non-controlling interest %	10%			10%			10%	10%
Comprehensive (loss) income attributable to NCI							$ 26	$ (9,065)
Additional income attributable to NCI							0	0
Net comprehensive (loss) income attributable to NCI							$ 26	$ (9,065)

Note 18 - Income Taxes (Details

Note 18 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Income Tax Expense (Benefit)	$ (2,871)	$ (10,811)	$ 1,013	$ (15,313)

Note 19 - Commitments and Con_3

Note 19 - Commitments and Contingencies (Details Textual) $ in Thousands, $ in Millions	Mar. 05, 2024 USD ($)	Dec. 02, 2022 USD ($)	Feb. 21, 2020 CAD ($)	Feb. 29, 2024 USD ($)	May 31, 2023 USD ($)	Feb. 28, 2023 USD ($)	Feb. 28, 2023 CAD ($)
Loss Contingency, Damages Sought, Value		$ 27,500
Financing Receivable, after Allowance for Credit Loss				$ 32,000	$ 103,401
Litigation Settlement, Amount Awarded to Other Party	$ 19,950
Loss Contingency Accrual				25,153	$ 25,000
Cannfections Group Inc. [Member] | High Park [Member]
Equity Method Investment, Ownership Percentage		50%
HEXO Acquisition [Member]
Loss Contingency Accrual				12,253
Craft Beverage Business Acquisition [Member]
Loss Contingency Accrual				$ 0
Tilray and High Park vs. 420 Investments Unpaid Debt Collection [Member]
Debt Instrument, Face Amount							$ 7
Tilray and High Park vs. 420 Investments Unpaid Debt Collection [Member] | Collectability of Receivables, Face Amount [Member]
Financing Receivable, after Allowance for Credit Loss							$ 7
Tilray and High Park vs. 420 Investments Unpaid Debt Collection [Member] | Collectability of Receivables Interest and Costs [member]
Interest Receivable						$ 2,800
Pending Litigation [Member] | The 420 Investments Ltd. Litigation [Member] | Damages [Member]
Loss Contingency, Damages Sought, Value			$ 110
Pending Litigation [Member] | The 420 Investments Ltd. Litigation [Member] | Aggravated Damages [Member]
Loss Contingency, Damages Sought, Value			$ 20

Note 19 - Commitments and Con_4

Note 19 - Commitments and Contingencies - Schedule of Commitments (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Total	$ 487,488
Total, 2024	120,974
Total, 2025	71,891
Total, 2026	8,973
Total, 2027	182,835
Total, thereafter	102,815
Material Purchase Obligations [Member]
Purchase obligations, total	49,159
Purchase obligations, 2024	21,587
Purchase obligations, 2025	27,572
Purchase obligations, 2026	0
Purchase obligations, 2027	0
Purchase obligations, thereafter	0
Capital Addition Purchase Commitments [Member]
Purchase obligations, total	822
Purchase obligations, 2024	822
Purchase obligations, 2025	0
Purchase obligations, 2026	0
Purchase obligations, 2027	0
Purchase obligations, thereafter	0
Long-term Debt, Excluding Convertible Debentures [Member]
Debt instrument	178,977	$ 161,707
Debt Instrument, 2024	12,535
Long-term debt repayment	44,319
Debt instrument, 2026	8,973
Debt instrument, 2027	10,335
Debt instrument, thereafter	102,815
Convertible Debentures [Member]
Debt instrument	258,530
Debt Instrument, 2024	86,030
Long-term debt repayment	0
Debt instrument, 2026	0
Debt instrument, 2027	172,500
Debt instrument, thereafter	$ 0

Note 20 - Net Revenue (Details

Note 20 - Net Revenue (Details Textual)	9 Months Ended
	Feb. 29, 2024
Number of Operating Segments	4

Note 20 - Net Revenue - Compone

Note 20 - Net Revenue - Components of Net Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Net revenue	$ 188,340	$ 145,589	$ 559,060	$ 442,936
Beverage Alcohol Business [Member]
Revenue	58,247	21,941	133,237	67,209
Excise taxes	(3,559)	(1,301)	(7,882)	(4,520)
Net revenue	54,688	20,640	125,355	62,689
Cannabis Segment [Member]
Revenue	85,236	61,118	276,676	203,503
Excise taxes	(21,804)	(13,569)	(75,797)	(47,486)
Net revenue	63,432	47,549	200,879	156,017
Tilray Pharma Segment [Member]
Net revenue	56,794	65,385	193,174	186,158
Wellness Business [Member]
Net revenue	$ 13,426	$ 12,015	$ 39,652	$ 38,072

Note 21 - Cost of Goods Sold -

Note 21 - Cost of Goods Sold - Components of Cost of Goods Sold (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Cost of goods sold	$ 138,944	$ 157,288	$ 418,059	$ 363,139
Beverage Alcohol Business [Member]
Cost of goods sold	35,836	10,663	77,615	32,932
Cannabis Segment [Member]
Cost of goods sold	42,518	80,362	139,507	137,800
Tilray Pharma Segment [Member]
Cost of goods sold	51,231	57,964	172,846	165,443
Wellness Business [Member]
Cost of goods sold	$ 9,359	$ 8,299	$ 28,091	$ 26,964

Note 22 - General and Adminis_3

Note 22 - General and Administrative Expenses (Details Textual) - 9 months ended Feb. 29, 2024 $ in Thousands, $ in Millions	USD ($)	CAD ($)
Accounts Receivable, Credit Loss Expense (Reversal)	$ 4,440	$ 6

Note 21 - General and Administr

Note 21 - General and Administrative Expenses - Components of General and Administrative Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Executive compensation	$ 1,585	$ 2,754	$ 4,757	$ 9,359
Office and general	4,190	6,799	20,423	20,011
Salaries and wages	19,588	13,621	52,310	38,407
Share-Based Payment Arrangement, Expense	8,059	9,630	24,517	29,766
Insurance	3,569	3,159	9,917	8,588
Professional fees	656	1,165	4,658	5,385
(Gain) loss on sale of capital assets	23	(15)	3	(2)
Travel and accommodation	1,246	1,104	3,727	3,484
Rent	1,024	782	3,457	2,387
Total	$ 39,940	$ 38,999	$ 123,769	$ 117,385

Note 23 - Restructuring Charg_2

Note 23 - Restructuring Charges (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Restructuring Costs	$ 5,178	$ 2,663	$ 8,748	$ 10,727
Cost Optimization [Member] | Distribution Business [Member]
Restructuring Costs		2,663		10,727
Restructuring and Related Cost, Expected Cost	$ 3		3
Employee Severance [Member] | Cost Reduction [Member]
Restructuring Costs			475
Employee Severance [Member] | Cost Optimization [Member] | Distribution Business [Member]
Restructuring Costs		$ 2,663
Employee Severance [Member] | HEXO Acquisition [Member]
Restructuring Costs			3,987
Facility Closing [Member] | CANADA
Restructuring and Related Cost, Incurred Cost				1,512,000
Facility Closing [Member] | Distribution Business [Member]
Restructuring and Related Cost, Incurred Cost				2,195,000
Facility Closing [Member] | Cost Optimization [Member] | Distribution Business [Member]
Restructuring Costs				1,599
Facility Closing [Member] | Truss Beverage Company [Member]
Restructuring Costs			3,454
One-time Termination Benefits [Member] | Cost Optimization [Member] | Distribution Business [Member]
Restructuring Costs			$ 832
Contract Termination [Member] | Cost Optimization [Member] | Distribution Business [Member]
Restructuring Costs				$ 2,758

Note 24 - Non-operating Incom_3

Note 24 - Non-operating Income (Expense) (Details Textual) - USD ($) $ in Thousands	3 Months Ended					9 Months Ended
	Feb. 29, 2024	Nov. 30, 2023	Aug. 31, 2023	Feb. 28, 2023	Aug. 31, 2022	Feb. 29, 2024	Feb. 28, 2023
Other Nonoperating Gains (Losses)	$ (8,245)			$ (1,370)		$ (9,427)	$ (7,545)
Stock Issued During Period, Value, Settlement of Convertible Securities	2,313	$ 2,313	$ 50,000
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	2,458		$ 7,891		$ 8,561
Cannfections Group Inc. [Member]
Equity Securities, FV-NI, Unrealized Gain (Loss)	$ (4,638)

Note 24 - Non-operating Incom_4

Note 24 - Non-operating Income (Expense) - Components of Non-operating Income (Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Change in fair value of convertible debenture payable	$ (6,311)	$ 207	$ (12,352)	$ (20,375)
Change in fair value of warrant liability	586	5,256	(1,365)	6,841
Foreign exchange loss (gain)	(3,302)	(1,955)	1,941	(26,621)
Loss on long-term investments	33	(925)	383	(2,529)
Other non-operating (losses) gains, net	(8,245)	(1,370)	(9,427)	(7,545)
Total	$ (17,239)	$ 1,213	$ (20,820)	$ (50,229)

Note 25 - Fair Value Measurem_3

Note 25 - Fair Value Measurements (Details Textual) $ in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024 USD ($)	Feb. 29, 2024 CAD ($)	Feb. 29, 2024 USD ($)	May 31, 2023 USD ($)
SweetWater, Montauk, and Truss [Member] | Contingent Consideration [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) From Foreign Exchange			$ (13,493)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)			$ (16,218)
SweetWater, Montauk, and Truss [Member] | Measurement Input, Discount Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.11		0.11
SweetWater, Montauk, and Truss [Member] | Measurement Input, Probability of Achievement [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.95		0.95
Acquisition of Montauk Brewing Company, Inc. [Member] | Contingent Consideration [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)			$ 3,111
Truss Beverage Company [Member] | Contingent Consideration [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) From Foreign Exchange	$ 760	$ 1,041
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)	4,181
Long-term Debt, Excluding Convertible Debentures [Member]
Long-Term Debt, Percentage Bearing Fixed Interest, Amount	3,846		3,846	$ 3,280
Convertible Debt [Member]
Convertible Debt	$ 258,530		$ 258,530	$ 464,070

Note 25 - Fair Value Measurem_4

Note 25 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Equity investments measured at fair value	$ 2,558	$ 2,144
Contingent consideration	0	(16,218)
Fair Value, Recurring [Member]
Cash and cash equivalents	146,253	206,632
Marketable securities	79,605	241,897
Convertible notes receivable	32,000	103,401
Equity investments measured at fair value	8,058	7,795
Warrant liability	(3,182)	(1,817)
Contingent consideration	(14,000)	(27,107)
Total recurring fair value measurements	165,383	410,233
Fair Value, Recurring [Member] | APHA 24 [Member]
APHA 24 Convertible debenture	(83,351)	(120,568)
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents	146,253	206,632
Marketable securities	79,605	241,897
Convertible notes receivable	0	0
Equity investments measured at fair value	1,104	1,056
Warrant liability	0	0
Contingent consideration	0	0
Total recurring fair value measurements	226,962	449,585
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | APHA 24 [Member]
APHA 24 Convertible debenture	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents	0	0
Marketable securities	0	0
Convertible notes receivable	0	0
Equity investments measured at fair value	1,454	1,088
Warrant liability	0	0
Contingent consideration	0	0
Total recurring fair value measurements	1,454	1,088
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | APHA 24 [Member]
APHA 24 Convertible debenture	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents	0	0
Marketable securities	0	0
Convertible notes receivable	32,000	103,401
Equity investments measured at fair value	5,500	5,651
Warrant liability	(3,182)	(1,817)
Contingent consideration	(14,000)	(27,107)
Total recurring fair value measurements	(63,033)	(40,440)
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | APHA 24 [Member]
APHA 24 Convertible debenture	$ (83,351)	$ (120,568)

Note 25 - Fair Value Measurem_5

Note 25 - Fair Value Measurements - Reconciliation of Level 3 Assets and Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands	9 Months Ended
	Feb. 29, 2024 USD ($)
Equity Investments [Member]
Balance	$ 5,651
Additions/(Repayments)	0
Redemption	0
Unrealized gain (loss) on fair value	(151)
Impairments	0
Balance	5,500
Warrant Liability [Member]
Balance	(1,817)
Additions/(Repayments)	0
Redemption	0
Unrealized gain (loss) on fair value	(1,365)
Impairments	0
Balance	(3,182)
Contingent Consideration [Member]
Balance	(27,107)
Additions/(Repayments)	(4,181)
Redemption	760
Unrealized gain (loss) on fair value	16,528
Impairments	0
Balance	(14,000)
Long-Term Debt [Member] | APHA 24 [Member]
Balance	(120,568)
Additions/(Repayments)	50,710
Redemption	0
Unrealized gain (loss) on fair value	(13,493)
Impairments	0
Balance	(83,351)
Notes Receivable [Member]
Balance	103,401
Additions/(Repayments)	0
Redemption	(28,720)
Unrealized gain (loss) on fair value	0
Impairments	(42,681)
Balance	$ 32,000

Note 25 - Fair Value Measurem_6

Note 25 - Fair Value Measurements - Inputs Used to Recognize Unrealized Gain (Loss) on Fair Value (Details) - Minimum [Member]	Feb. 29, 2024 yr
Valuation Technique, Option Pricing Model [Member] | Measurement Input, Price Volatility [Member]
Debt instrument, measurement input	0.50
Warrant liability, measurement input	0.50
Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Term [Member]
Debt instrument, measurement input	0.3
Warrant liability, measurement input	1.6
Valuation Technique, Discounted Cash Flow [Member] | Measurement Input, Discount Rate [Member]
Contingent consideration, measurement input	0.11
Valuation Technique, Discounted Cash Flow [Member] | Measurement Input, Conversion Rate [Member]
Contingent consideration, measurement input	0.95

Note 26 - Segment Reporting (De

Note 26 - Segment Reporting (Details Textual) $ in Thousands	3 Months Ended		6 Months Ended	9 Months Ended
	Feb. 29, 2024 USD ($)	Feb. 28, 2023 USD ($)	Feb. 29, 2024	Feb. 29, 2024 USD ($)	Feb. 28, 2023 USD ($)
Number of Reportable Segments			4
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Major Customers [Member]
Number Of Major Customers	0	0		0	0
Advisory Services Agreement With HEXO [Member] | Advisory Services Revenue [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 0	$ 8,667		$ 1,500	$ 24,302

Note 26 - Segment Reporting - S

Note 26 - Segment Reporting - Schedule of Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Net revenue	$ 188,340	$ 145,589	$ 559,060	$ 442,936
Cost of goods sold	138,944	157,288	418,059	363,139
Gross Profit	49,396	(11,699)	141,001	79,797
Cannabis Segment [Member]
Net revenue	63,432	47,549	200,879	156,017
Cost of goods sold	42,518	80,362	139,507	137,800
Gross Profit	20,914	(32,813)	61,372	18,217
Revenue	85,236	61,118	276,676	203,503
Excise taxes	(21,804)	(13,569)	(75,797)	(47,486)
Cannabis Segment [Member] | Medical Cannabis Products [Member]
Revenue	6,363	6,035	18,793	18,920
Cannabis Segment [Member] | Adult-use Cannabis Products [Member]
Revenue	62,107	45,318	205,350	156,063
Cannabis Segment [Member] | Wholesale Cannabis Products [Member]
Revenue	2,764	58	12,348	686
Cannabis Segment [Member] | International Cannabis Products [Member]
Revenue	14,002	9,707	40,185	27,834
Beverage Alcohol Business [Member]
Net revenue	54,688	20,640	125,355	62,689
Cost of goods sold	35,836	10,663	77,615	32,932
Gross Profit	18,852	9,977	47,740	29,757
Revenue	58,247	21,941	133,237	67,209
Excise taxes	(3,559)	(1,301)	(7,882)	(4,520)
Tilray Pharma Segment [Member]
Net revenue	56,794	65,385	193,174	186,158
Cost of goods sold	51,231	57,964	172,846	165,443
Gross Profit	5,563	7,421	20,328	20,715
Wellness Business [Member]
Net revenue	13,426	12,015	39,652	38,072
Cost of goods sold	9,359	8,299	28,091	26,964
Gross Profit	$ 4,067	$ 3,716	$ 11,561	$ 11,108

Note 26 - Segment Reporting - G

Note 26 - Segment Reporting - Geographic Net Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Net revenue	$ 188,340	$ 145,589	$ 559,060	$ 442,936
North America [Member]
Net revenue	117,524	70,463	325,664	228,866
EMEA [Member]
Net revenue	67,143	71,111	222,139	199,867
Rest of World [Member]
Net revenue	$ 3,673	$ 4,015	$ 11,257	$ 14,203

Note 26 - Segment Reporting -_2

Note 26 - Segment Reporting - Geographic Capital Assets (Details) - USD ($) $ in Thousands	Feb. 29, 2024	May 31, 2023
Capital assets	$ 578,783	$ 429,667
North America [Member]
Capital assets	473,779	319,173
EMEA [Member]
Capital assets	101,271	107,131
Rest of World [Member]
Capital assets	$ 3,733	$ 3,363

Note 27 - Subsequent Events (De

Note 27 - Subsequent Events (Details Textual) - Subsequent Event [Member] - APHA 24 [Member] $ in Millions	Apr. 09, 2024 USD ($) shares
Stock Issued During Period, Value, Repurchase of Debt | $	$ 41.9
Stock Issued During Period, Shares, Repurchase of Debt (in shares) | shares	25,000,000